<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013112</article-id><article-id pub-id-type="pmc">PMC11862918</article-id><article-id pub-id-type="doi">10.3389/fped.2025.1506690</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Review of rhythm disturbances in patient after fontan completion: epidemiology, management, and surveillance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wall</surname><given-names>Kevin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2877730/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Hebson</surname><given-names>Camden</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2827972/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Souza</surname><given-names>Roshan</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2905755/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Balaji</surname><given-names>Seshadri</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2730815/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Pediatrics, Division of Cardiology, University of Alabama at Birmingham</institution>, <addr-line>Birmingham, AL</addr-line>, <country>United States</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Department of Pediatrics, Division of Cardiology, Seattle Children&#x02019;s Hospital</institution>, <addr-line>Seattle, WA</addr-line>, <country>United States</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Department of Pediatrics, Division of Cardiology, Oregon Health &#x00026; Science University</institution>, <addr-line>Portland, OR</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Nathalie Dedieu, Paediatric Cardiology Consultant at Great Ormond Street Hospital, United Kingdom</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Roman A. Gebauer, Leipzig University, Germany</p><p>Floris E.A. Udink ten Cate, Radboud University Medical Center, Netherlands</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Seshadri Balaji <email>balajis@ohsu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>1506690</elocation-id><history><date date-type="received"><day>05</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Wall, Hebson, D'Souza and Balaji.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wall, Hebson, D'Souza and Balaji</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>The Fontan operation is commonly associated with alterations in heart rhythms, both tachycardic and bradycardic. Despite modifications to attempt to mitigate these complications, arrythmias still frequently occur. The purpose of this review is to examine the literature regarding the scope of the problem, therapeutic options, and current recommendations regarding screening and surveillance.</p></sec><sec><title>Recent findings</title><p>Modifications to the original Fontan procedure, antiarrhythmic medications, and improvements in catheter ablation procedures have improved the management of patients with arrhythmias following Fontan palliation. There is growing interest in the role of junctional rhythm in the role of Fontan dysfunction. While chronotropic incompetence has often been blamed for poor exercise testing, there is evidence that decreased performance may be related to ventricular filling and Fontan hemodynamics.</p></sec><sec><title>Summary</title><p>Tachyarrhythmias are an important cause of mortality and morbidity after the Fontan operation. Prompt and aggressive management of arrhythmias with the goal of maintaining sinus rhythm is vital. Management strategies such as anti-arrhythmic medications, ablation, anti-tachycardia pacing and Fontan conversion should be seen as complementary and used early to prevent hemodynamic deterioration. Bradyarrythmias likely also contribute to Fontan failure. Pacing is the primary management strategy with evidence supporting use of atrial pacing. However, ventricular pacing seems to often lead to deleterious effects. Current guidelines recommend surveillance with Holter monitor every 2&#x02013;3 years in adolescents and every 1&#x02013;2 years in adults. Future directions for research include further assessment of junctional rhythm and its management as well as further identifying patients in which pacing would be beneficial.</p></sec></abstract><kwd-group><kwd>fontan</kwd><kwd>junctional rhythm</kwd><kwd>tachyarrhythmia</kwd><kwd>antiarrhythmic drugs</kwd><kwd>arrhythmia</kwd><kwd>congenital heart disease</kwd><kwd>surveillance</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><equation-count count="0"/><ref-count count="110"/><page-count count="14"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Pediatric Cardiology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The Fontan operation transformed the outlook for children born with a single ventricle. However, it is a fragile circulatory arrangement with a tendency to develop a multitude of problems (<xref rid="B1" ref-type="bibr">1</xref>). Specifically, arrhythmias are one of the commonest causes of morbidity and mortality in these patients (<xref rid="B1" ref-type="bibr">1</xref>). Despite surgical modifications like the intracardiac lateral tunnel (ILT) and the extracardiac conduit (ECC) Fontan, arrhythmias continue to occur in a significant number of patients (<xref rid="B1" ref-type="bibr">1</xref>). Arrhythmias may present in a wide variety of ways ranging from the subtle (vague or mild symptoms of fatigue) to the catastrophic (syncope or rarely, cardiac arrest). Some, with arrhythmias may even be detected only at routine follow up. Yet another important consideration in Fontan patients is their risk for acute thromboembolic events (<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>). Underlying structural problems including poor ventricular function, and valve regurgitation may predispose to arrhythmias. Arrhythmias also can lead to worsening of cardiac ventricular function. One report showed that &#x0223c;40% of patients developed ventricular dysfunction after the first onset of an arrhythmia (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Supraventricular tachycardia (SVT) has also been shown to be associated with a six-fold increase in transplantation and death (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>Physicians caring for these patients must be aware of these arrhythmias, including their unique presentations after the Fontan, the diagnostic approach one should take, and the treatment options available. Regular surveillance to detect pre-clinical arrhythmias and prompt recognition and management of clinical arrhythmias are keys to achieving this goal. In this review, we aim to review tachyarrhythmias and bradyarrhythmias that arise after Fontan palliation, including a summary of the literature and an up-to-date approach to these often-challenging clinical presentations.</p></sec><sec id="s2"><title>Tachycardia in patients after fontan completion</title><p>In the original, so-called atrio-pulmonary connection (APC) Fontan, the presence of extensive surgical scars in the right atrium (RA) combined with pressure and volume overload of the RA (which lead to stretching of the scars) is thought to predispose to the development of arrhythmias (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B10" ref-type="bibr">10</xref>). While surgical scars are still present after the ILT and the ECC, they are fewer. Also, the ILT leaves most of the RA in the lower pressure pulmonary venous side of the atrium (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). The ECC leaves the entire RA on the low pressure pulmonary venous side (<xref rid="B13" ref-type="bibr">13</xref>). On the other hand ventricular tachyarrhythmia (VT) is predominantly seen in patients with ventricular surgical scars and in those with a dominant right ventricle (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>).</p><p>The development of any tachyarrhythmia is an independent predictor of poor clinical outcome and tachyarrhythmias are associated with Fontan failure, sudden cardiac death) SCD, and mortality (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>). In one study, the 15-year survival after development arrhythmias was 70% and freedom from Fontan failure was 44% (<xref rid="B20" ref-type="bibr">20</xref>). Atrial arrhythmias are associated with a six-fold increase in transplantation and death (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Given the fragile nature of the Fontan circulation, prompt recognition and management of tachyarrhythmias are key to improving patient quality and quantity of life. Some arrhythmias, especially intra atrial reentry tachycardia (IART) may appear innocuous and resemble either sinus or a &#x0201c;junctional&#x0201d; tachycardia on electrocardiogram (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). An example of IART may be seen in <xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>. The presence of extensive scarring in the atrium can lead to low amplitude and fractionated p waves which may be hard to see (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). A high index of suspicion is important in making a timely diagnosis. In the next sections, we review the various types of tachyarrhythmias.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>IART in a young adult with intra-cardiac lateral tunnel fontan.</p></caption><graphic xlink:href="fped-13-1506690-g001" position="float"/></fig><sec id="s2a"><title>Supraventricular tachycardia</title><p>The APC type of Fontan is associated with a high incidence of SVT. SVT occurred in the early post-operative period in 10%&#x02013;30% of patients followed by a steady incidence during follow-up (<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>) Late arrhythmias occurred in up to 80% by &#x0003e;30 days post operative period (median time of 12 years after surgery) (<xref rid="B27" ref-type="bibr">27</xref>&#x02013;<xref rid="B29" ref-type="bibr">29</xref>). Early post-operative SVT occurs in 25% patients after the ILT (<xref rid="B30" ref-type="bibr">30</xref>) and 14% after the ECC Fontan (<xref rid="B29" ref-type="bibr">29</xref>). As for late post-operative SVT, it has been noted in 32% of ILT and 6%&#x02013;17% of ECC by 1&#x02013;5 years post-operative (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B28" ref-type="bibr">28</xref>).</p><p>Much of what we know about the specific type of SVT's seen in these patients comes from studies describing outcomes after catheter ablation for SVT (<xref rid="B21" ref-type="bibr">21</xref>). The most common type of SVT in these patients is IART (&#x0223c;93%) (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Patients, however, can also have atrioventricular re-entrant tachycardia (AVRT) and atrioventricular nodal re-entrant tachycardia (AVNRT) which occur in &#x0223c;4% (<xref rid="B21" ref-type="bibr">21</xref>). As patients age, atrial fibrillation becomes the dominant arrhythmia, and has been noted in &#x02212;2%&#x02013;40% (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B33" ref-type="bibr">33</xref>). However, other mechanisms such as AVRTs utilizing either an accessory pathway or twin atrioventricular nodes, AVNRT, ectopic atrial tachycardias, and junctional tachycardia are described (<xref rid="B34" ref-type="bibr">34</xref>).</p></sec><sec id="s2b"><title>Medical management of SVT</title><p>Prompt treatment is a must for episodes causing significant hemodynamic compromise. However, even in those who may tolerate the tachyarrhythmia acutely, conversion to sinus rhythm as soon as possible is of utmost importance (<xref rid="B22" ref-type="bibr">22</xref>). The importance of atrial kick in maintaining adequate cardiac output in the Fontan circulation cannot be overstated. Therefore, in patients with the Fontan physiology, the goal should be rhythm control rather than rate control (<xref rid="B35" ref-type="bibr">35</xref>).</p><p>For acute conversion, adenosine can be used for SVT involving the atrioventricular node after evaluating baseline ventricular function with an echocardiogram and electrocardiogram. However, such SVT are less common. Therefore, most patients with IART or atrial fibrillation need cardioversion (<xref rid="B22" ref-type="bibr">22</xref>). Most centers use direct current cardioversion. If the patient is stable with an adequate blood pressure, medications can be tried before cardioversion, although it is not considered first line therapy. Options for pharmacologic cardioversion include intravenous (IV) Ibutilide, IV sotalol, IV procainamide, and IV amiodarone (<xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B37" ref-type="bibr">37</xref>). Due to the risk of development of intracardiac thrombi with untreated atrial arrhythmias &#x0003e;24&#x02013;48&#x02005;hour duration, pre-procedural transesophageal echocardiogram (to assess for thrombus), anticoagulation, and conscious sedation is necessary (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>).</p><p>Chronic therapy options include anti-arrhythmic drugs, catheter ablation, anti-tachycardia pacing and the surgical MAZE procedure (<xref rid="B35" ref-type="bibr">35</xref>). A summary of medication options for long term management of IART including dosage, side effects, and monitoring considerations can be found in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>. The goal of chronic medical management is maintenance of sinus rhythm. The choice of medication primarily depends upon whether or not there is normal ventricular function. If so, class 1c agents (propafenone or flecainide) or sotalol (class III agent) are typically chosen as first line medication. If not, amiodarone or dofetilide may be considered. Amiodarone may also be employed as a second line agent in patients with normal ventricular function (<xref rid="B35" ref-type="bibr">35</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Chronic rhythm control in adults with fontan circulation and IART.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Medication</th><th valign="top" align="center" rowspan="1" colspan="1">Indication</th><th valign="top" align="center" rowspan="1" colspan="1">Dose</th><th valign="top" align="center" rowspan="1" colspan="1">Side effects contraindications</th><th valign="top" align="center" rowspan="1" colspan="1">Monitoring issues</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Flecainide (class IC)</td><td valign="top" align="left" rowspan="1" colspan="1">First line in patients with normal ventricular function</td><td valign="top" align="left" rowspan="1" colspan="1">Dose adjusted based on serum levels:<break/>Initial: 50&#x02005;mg bid<break/>Increase by 50&#x02005;mg bid at 4-day intervals; maximum dose: 300&#x02005;mg/day</td><td valign="top" align="left" rowspan="1" colspan="1">Black box warning with increased risk of ventricular arrhythmias as well as mortality in patients with ventricular dysfunction or coronary artery disease<break/>Proarrhythmic (VT, bradycardia, AV block)<break/>QRS prolongation<break/>Has potential to convert atrial arrhythmias into 1:1 conduction due to negative chronotropic effects&#x02014;should initiate concurrent AV node blocking medication</td><td valign="top" align="left" rowspan="1" colspan="1">Dosing based on serum levels which need to be intermittently monitored: therapeutic trough concentration is between 0.2 and 1&#x02005;mcg/ml<break/>Follow daily ECG for QRS prolongation while inpatient until therapeutic</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Propafenone (class IC)</td><td valign="top" align="left" rowspan="1" colspan="1">First line in patients with normal ventricular function</td><td valign="top" align="left" rowspan="1" colspan="1">Immediate release:<break/>Initial: 150&#x02005;mg every 8&#x02005;h; may increase after 3- to 4-day intervals; may increase to 300&#x02005;mg every 8&#x02005;h.<break/>Extended release:<break/>Initial: 225&#x02005;mg every 12&#x02005;h; may increase after 5-day intervals; may increase to 425&#x02005;mg every 12&#x02005;h</td><td valign="top" align="left" rowspan="1" colspan="1">Black box warning with increased risk of ventricular arrhythmias as well as mortality in patients with ventricular dysfunction or coronary artery disease<break/>Proarrhythmic (VT, bradycardia, AV block)<break/>QRS prolongation<break/>Has potential to convert atrial arrhythmias into 1:1 conduction due to negative chronotropic effects&#x02014;should initiate concurrent AV node blocking medication<break/>Central nervous system side effects such as dizziness, nausea, unusual taste, and blurred vision</td><td valign="top" align="left" rowspan="1" colspan="1">Check ECG for QRS prolongation daily while inpatient until therapeutic</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sotalol (class III)</td><td valign="top" align="left" rowspan="1" colspan="1">First line in patients with normal ventricular function</td><td valign="top" align="left" rowspan="1" colspan="1">Initial dose: 80&#x02005;mg<break/>Dosing frequency based on calculated creatinine clearance:<break/>&#x0003e; 60&#x02005;ml/min: bid dosing<break/>40&#x02013;60&#x02005;ml/min: daily dosing<break/>&#x0003c; 40&#x02005;ml/min: contraindicated<break/>Adjustment: may increase every 2&#x02013;3 days up to 320&#x02005;mg, given in 2 or 3 divided doses</td><td valign="top" align="left" rowspan="1" colspan="1">Can prolong the QT interval, so check QT interval before administering (contraindicated if &#x0003e; 450&#x02005;ms)<break/>Proarrhythmic (torsade); exercise caution when combining with other QT-prolonging medications (antimicrobial, antiemetic, etc)</td><td valign="top" align="left" rowspan="1" colspan="1">Check ECG for QRS prolongation daily while inpatient (adjust dose if QTc &#x0003e; 500&#x02005;ms)<break/>Monitor ECG intermittently once stable</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amiodarone (class III)</td><td valign="top" align="left" rowspan="1" colspan="1">First line in patients with ventricular dysfunction<break/>Second line if function is normal</td><td valign="top" align="left" rowspan="1" colspan="1">200&#x02005;mg daily</td><td valign="top" align="left" rowspan="1" colspan="1">Pulmonary and liver toxicity, corneal microdeposits, photosensitivity, thyroid dysfunction [hypo- or hyperthyroidism, especially in women post Fontan and those with BMI &#x0003c; 21 kg/m2 (<xref rid="B35" ref-type="bibr">35</xref>)], and adverse cardiac effects (e.g., bradycardia, torsades de pointes)</td><td valign="top" align="left" rowspan="1" colspan="1">Cardiac: baseline testing of ICD threshold if one present<break/>Pulmonary: chest radiograph at baseline and yearly for asymptomatic patients; PFT if symptoms develop<break/>Thyroid: baseline TSH and FT4 at baseline; serial testing 3&#x02013;4 months post initiation, then yearly<break/>Liver: baseline AST/ALT, repeat 6 months post initiation, then yearly<break/>Ophthalmologic: yearly eye exam</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dofetilide (class III)</td><td valign="top" align="left" rowspan="1" colspan="1">Second line therapy as alternative to amiodarone in patients with ventricular dysfunction</td><td valign="top" align="left" rowspan="1" colspan="1">Dofetilide dosing is based on creatinine clearance and calculated QTc:<break/>Initial dose with calculated creatinine clearance:<break/>&#x0003e; 60&#x02005;ml/min: 500&#x02005;mcg bid<break/>40&#x000a0;&#x02013;60&#x02005;ml/min: 250&#x02005;mcg bid<break/>20&#x000a0;&#x02013;40&#x02005;ml/min: 125&#x02005;mcg bid<break/>&#x0003c; 20&#x02005;ml/min: contraindicated<break/>Subsequent doses adjusted if QTc increases &#x0003e; 15% or QTc &#x0003e; 500&#x02005;ms<break/>Starting dose: adjusted dose:<break/>500&#x02005;mcg bid 250&#x02005;mcg bid<break/>250&#x02005;mcg bid 125&#x02005;mcg bid<break/>123&#x02005;mcg daily 125&#x02005;mcg daily</td><td valign="top" align="left" rowspan="1" colspan="1">Contraindicated in pregnancy (class C), patients with LQTS, patients on dialysis or with renal disease, or with vomiting or electrolyte derangements<break/>Adverse Effects: Proarrhythmic&#x02014;Torsades de pointes in 1&#x02013;3% of patients, may induce of worsen ventricular dysrhythmias, possibly inducing PMVT<break/>Side Effects: Rash, diarrhea, dizziness, sweating, vomiting, loss of appetite</td><td valign="top" align="left" rowspan="1" colspan="1">Follow QTc to monitor for signs of prolongation. FDA recommends admission for initiation with continuous ECG and calculating QTc 2&#x02013;3&#x02005;h after doses 2&#x02013;5 after starting and monitor for minimum of 3 days</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>IART, intra atrial reentry tachycardia; AV, atrioventricular; ECG, electrocardiogram; VT, ventricular tachycardia; PMVT, polymorphic ventricular tachycardia; QTc, adjusted QT interval; LQTS, long QT syndrome; PFT, pulmonary function testing.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Catheter ablation</title><p>Catheter ablation of SVT in Fontan patients is a highly specialized procedure performed by electrophysiology physicians with training and experience in congenital heart disease (<xref rid="B18" ref-type="bibr">18</xref>). These procedures entail prolonged case time, are complex, and require highly specialized equipment including three-dimensional mapping (3D) technology, intracardiac echocardiogram and the use of specialized catheters. With large atrial size, multiple scars and pathways, the APC Fontan patients pose significant challenges during ablation as there may be multiple circuits with the rhythm morphing from one to the other (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B40" ref-type="bibr">40</xref>). In APC Fontan patients, studies have described an acute success rate varying from 78%&#x02013;94%, with partial success achieved in 6%&#x02013;13%. The recurrence rate is high (20%&#x02013;50%), and multiple ablations are needed in &#x0223c;5% of patients (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B42" ref-type="bibr">42</xref>). Complications of ablation include complete atrioventricular block requiring pacemaker placement, thrombus and embolism, rarely fatality (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B42" ref-type="bibr">42</xref>). Despite these risks at 24 months following ablation, there was an improvement in overall arrhythmia score. This is likely postulated due to either ablation of all tachycardia foci or modification of the dominant arrhythmia substrate (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B42" ref-type="bibr">42</xref>). The acute success rate has been described to be higher in ILT patients (<xref rid="B18" ref-type="bibr">18</xref>), however, they also have a high recurrence rate (<xref rid="B18" ref-type="bibr">18</xref>). ECC patients require puncture of the Fontan baffle to access the atrial myocardium, without significant consequent risks (<xref rid="B42" ref-type="bibr">42</xref>). In the ECC group, the most common site of arrhythmias is the cavo-tricuspid isthmus, with consequently higher success rates for ablation (<xref rid="B43" ref-type="bibr">43</xref>). Reports of ablation of AVNRT and AVRT using an accessory pathway or twin AV nodes are confined to small case series (<xref rid="B42" ref-type="bibr">42</xref>). Any ablation in a Fontan patient must surmount a few anatomical challenges and therefore must be performed at specialized centers with experienced personnel.</p></sec><sec id="s2d"><title>Summary of SVT management</title><p>It is our practice that an in-depth discussion is pursued with the family regarding ablation vs. medical management, emphasizing that these therapies are complementary and not contradictory; most patients will need both. After a detailed conversion with shared decision making, we would proceed with either a class 1C or class III medication for rhythm control. It is our practice to typically admit patients for initiation of medication over the course of 2&#x02013;3 days to ensure stability. If they tolerate this, we continue therapy as an outpatient with frequent ambulatory monitoring to assess adequacy of treatment. In select patients, catheter ablation may be considered as a first line therapy. When ablation is successful, patients may be monitored without need for initiating anti-arrhythmic therapy. If unsuccessful or only partially successful, we would initiated medications and monitor as above.</p></sec><sec id="s2e"><title>Ventricular tachycardia</title><p>Ventricular tachycardias are less frequent in the Fontan population (3%&#x02013;10%) and non-sustained ventricular arrhythmias are typically discovered during surveillance (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B13" ref-type="bibr">13</xref>). However, the long-term implications of this arrhythmia, especially in relation to risk for sudden death, is unclear. This is an important consideration given that reports show that the mode of death is sudden (and presumably arrhythmic) in &#x02212;3%&#x02013;12% of Fontan patients (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B33" ref-type="bibr">33</xref>).</p><p>VT can be difficult to manage in Fontan patients. While beta blockers may provide some protective effect, they cannot be relied upon to be the mainstay of treatment in patients who have VT associated with major symptoms such as syncope or near-syncope (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B44" ref-type="bibr">44</xref>). ICD placement may need to be considered. Given the anatomical constraints imposed by the Fontan circulation, ICD's are hard to place (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>). The subcutaneous ICD may be an excellent option in many patients (<xref rid="B42" ref-type="bibr">42</xref>). Major anti-arrhythmic drugs such as sotalol and amiodarone should be considered in patients with VT.</p></sec><sec id="s2f"><title>Anti-arrhythmic drugs</title><p>Vaughan-Williams class Ic/III (Sodium and Potassium channel blockade) rhythm-control agents are initiated in the hospital with electrocardiogram monitoring. Class I agents include flecainide and propafenone and class III agents commonly used are Amiodarone, Sotalol and Dofetilide (<xref rid="B36" ref-type="bibr">36</xref>). Sotalol and Dofetilide can cause prolongation of the QT interval and torsades as a lethal proarrhythmia (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>). Hence, careful monitoring of the QT at the time of initiation of these two drugs is critical to long term use (<xref rid="B49" ref-type="bibr">49</xref>). Amiodarone, even though is most effective drug in the long-term, is disadvantageous for multiple reasons, especially its association with multiple side effects when used long term (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B50" ref-type="bibr">50</xref>). Therefore, it is important to think of an &#x0201c;exit-strategy&#x0201d; (such as ablation, Fontan conversion surgery, and transplantation) out of chronic amiodarone use. If possible long-term use should be avoided.</p><p>Pharmacologic therapy is associated with a &#x0003e;90% arrhythmia recurrence rate within 3 years (<xref rid="B36" ref-type="bibr">36</xref>). Complete control of arrhythmia was seen in 63% whereas 35% of partial benefit was seen with medical therapy alone (<xref rid="B50" ref-type="bibr">50</xref>). Discontinuation due to toxicity is common accounting for 42% of AAD (<xref rid="B50" ref-type="bibr">50</xref>). In one cohort on Amiodarone, 30% developed thyrotoxicosis and 14% hypothyroidism (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B50" ref-type="bibr">50</xref>).</p><p>Class 1 c agents must be used with caution for two main reasons. Firstly, they can cause QRS duration prolongation and ventricular arrhythmias (<xref rid="B35" ref-type="bibr">35</xref>). Secondly, they can slow down the rate of atrial arrhythmias, which can be conducted at a higher ratio to the ventricle. For instance, a stable patient with a IART rate of 300, and 2:1 conduction giving a ventricular rate of 150 may become unstable if their IART rate is reduced (for example to 200) with consequent 1:1 atrioventricular (AV) nodal conduction. Hence class1c agents should always be combined with high doses of AV node blocking agents when used in this patient population (<xref rid="B35" ref-type="bibr">35</xref>).</p></sec><sec id="s2g"><title>Fontan conversion</title><p>The Fontan conversion operation is an option for patients with an APC faced with intractable arrhythmias. This includes resection of the enlarged RA, atrial septectomy, right-sided or bi-atrial maze cryoablation, extracardiac conduit placement (inferior vena cava to pulmonary artery), bidirectional Glenn, and, if needed, placement of an epicardial pacemaker (<xref rid="B8" ref-type="bibr">8</xref>). This surgery has a procedural mortality risk of 0.9%&#x02013;3% in the perioperative period and a further late mortality 3&#x02013;5.4% (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B51" ref-type="bibr">51</xref>). However, patients have been shown to have a freedom from atrial tachycardia of 77% at 10 years and freedom from cardiac death/transplant of 90% at 5 years, 84% at 10 years, and 66% at 15 years (<xref rid="B52" ref-type="bibr">52</xref>). High-risk characteristics for the operation at the conversion include right dominant ventricle, cardiopulmonary bypass (CPB) &#x0003e;240&#x02005;min, ascites, protein losing enteropathy (PLE) and those having bi-atrial MAZE operation (<xref rid="B52" ref-type="bibr">52</xref>).</p><p>The 2014 HRS/PACE guidelines recommended a modified right atrial MAZE procedure in all Fontan conversion surgeries, including those without prior atrial arrhythmias (<xref rid="B35" ref-type="bibr">35</xref>). On the other hand, a left atrial/biatrial Cox MAZE III procedure is chiefly used in those with a known left atrial arrhythmia or atrial fibrillation (AF) (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B51" ref-type="bibr">51</xref>). Patients who are felt to be too high risk for a Fontan conversion operation, especially those with severe ventricular dysfunction or PLE, should be referred for transplantation.</p></sec><sec id="s2h"><title>Sudden death</title><p>Arrhythmias as a cause of SCD has been noted to have an incidence of 3%&#x02013;12% and occur during late follow-up (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B53" ref-type="bibr">53</xref>). Risk factors for sudden death include atrioventricular valve replacement at time of Fontan operation and a Fontan pressure &#x0003e;20&#x02005;mmHg (<xref rid="B6" ref-type="bibr">6</xref>). Conversely, the presence of pre-operative sinus rhythm has been shown to be protective (<xref rid="B17" ref-type="bibr">17</xref>). Risk stratification to predict SCD is still in its infancy and further studies are needed to identify which patients would benefit from implantable cardioverter defibrillator (ICD) placement.</p></sec><sec id="s2i"><title>Antitachycardia pacing &#x00026; ICD</title><p>Antitachycardia pacing can be used to overdrive pace the patient out of SVT, specifically IART (<xref rid="B3" ref-type="bibr">3</xref>). The enthusiasm for antitachycardia pacing has waned after the introduction of catheter ablation. However, it can still have a role in select patients with recalcitrant arrhythmias (<xref rid="B3" ref-type="bibr">3</xref>). Patients with resuscitated cardiac arrest or hemodynamically unstable ventricular arrhythmia are usually treated with an ICD. Despite SCD being the cause of death in &#x02212;20%&#x02013;25% of adult patients with a Fontan, the lack of adequate risk prediction methods makes it difficult to place a prophylactic ICD in these patients.</p></sec><sec sec-type="conclusions" id="s2j"><title>Conclusions</title><p>Tachyarrhythmias are an important cause of mortality and morbidity after the Fontan operation. While the change from APC to ILT/ECC has reduced the incidence and hemodynamic deterioration associated with atrial arrhythmias, they have not eliminated the problem. An important key to early detection is a high index of suspicion. Prompt and aggressive management of arrhythmias with the goal of maintaining sinus rhythm is vital. Management strategies such as anti-arrhythmic medications, ablation, anti-tachycardia pacing and Fontan conversion should be seen as complementary and used early to prevent hemodynamic deterioration.</p></sec></sec><sec id="s3"><title>Bradycardia in patients after the fontan procedure</title><p>Bradyarrhythmias present a challenge in patients after completion of the Fontan procedure with clinical complications that can be highly consequential. While the association between tachyarrhythmias and poor outcomes is well-established in the Fontan population, bradyarrhythmias may also have serious clinical consequences, as even small alterations in the hemodynamics of these patients can lead to adverse outcomes including Fontan failure, Fontan associated liver disease, and even mortality (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). While tachyarrhythmias are often easily recognized (due to the severity of their symptoms), bradyarrhythmias can be insidious, with prolonged periods of being asymptomatic prior to discovery (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B56" ref-type="bibr">56</xref>). A study by Carins et al. from the Australia-New Zealand Fontan registry demonstrated a high incidence of Fontan failure after onset of bradyarrhythmias including sinus node dysfunction (SND) and AV node disease causing heart block (<xref rid="B33" ref-type="bibr">33</xref>). In this section, we will review the existing literature on bradyarrhythmias in patients with Fontan physiology.</p><sec id="s3a"><title>Sinus node dysfunction</title><p>SND is the most commonly encountered bradyarrhythmia in patients after Fontan completion with an estimated incidence between 9%&#x02013;60% (<xref rid="B56" ref-type="bibr">56</xref>&#x02013;<xref rid="B62" ref-type="bibr">62</xref>). However, this underestimates the issue, as patients with sinus node dysfunction can be asymptomatic (<xref rid="B33" ref-type="bibr">33</xref>). SND can be defined as an average resting heart rate greater than two standard deviations below the mean, predominant junctional rhythm, and/or sinus pauses of 3 or more seconds (<xref rid="B63" ref-type="bibr">63</xref>). SND typically begins subtly with progressively decreasing periods of sinus rhythm and greater periods spent in bradycardia and junctional rhythm. While sinus bradycardia and pauses may cause symptoms such as fatigue, exertional shortness of breath or dizziness/syncope, many patients &#x0201c;adapt&#x0201d; to their chronic disability and may not endorse any symptoms (<xref rid="B64" ref-type="bibr">64</xref>).</p><p>The APC Fontan is known to have a high incidence of SND, up to 50% at 10&#x02013;15 years (<xref rid="B12" ref-type="bibr">12</xref>). The high frequency is attributed to the extensive atrial tissue manipulation required during surgery, which likely leads to trauma to the sinus node or compromise of the arterial supply (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Others have proposed theories to explain why the incidence of sinus node dysfunction increases with including abnormal right-sided hemodynamics, atrioventricular valve regurgitation leading to atrial distention, and multiple suture lines near or around the sinus node (<xref rid="B63" ref-type="bibr">63</xref>). Alternative surgical techniques including the ILT and ECC have sought, in part, to mitigate against these risk factors (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B65" ref-type="bibr">65</xref>&#x02013;<xref rid="B67" ref-type="bibr">67</xref>).</p><p>With the ILT, the placement of an intra-atrial baffle leads to less of the atrial wall exposed to higher pressure and thus arrhythmia-generating distension (<xref rid="B68" ref-type="bibr">68</xref>). The downside is that there is suturing close to the sinus node during the baffling process. In contrast, the ECC eliminates the need for dissection and suture lines near the SA node as well as protecting against atrial distention (<xref rid="B68" ref-type="bibr">68</xref>). However, the need for harvesting an atrial cuff to allow for inferior anastomosis may lead to a higher-than-expected incidence of arrhythmias (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Despite these alterations in surgical technique, SND occurs in both the immediate post-operative period as well as late term follow-up.</p></sec><sec id="s3b"><title>Early SND</title><p>The incidence of SND in the immediate post-operative (Fontan) period is variably estimated between 2% and 25% (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). While a majority of patients do not require pacing prior to discharge, there is evidence that the presence of SND within the first several days post-operatively may predict the development of both late onset sinus node dysfunction and tachyarrhythmias (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B72" ref-type="bibr">72</xref>). Studies have compared the rates of early SND after each approach to Fontan completion, with conflicting results. Three groups found a higher incidence in the ILT compared to ECC patients (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>), with each of these being retrospective single center studies. Conversely, several studies have demonstrated no significant difference between the techniques or even a higher incidence in the ECC patients (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B75" ref-type="bibr">75</xref>&#x02013;<xref rid="B78" ref-type="bibr">78</xref>). These were also retrospective studies, but include several multicenter and multi-national cohorts. A metanalysis from Li et al. in 2017 included each of the afore-mentioned studies and examined the existing data from these studies (<xref rid="B18" ref-type="bibr">18</xref>). The conclusion was that while odds of SND was lower in the ECC group, this did not reach statistical significance (<italic>p</italic>&#x02009;=&#x02009;0.06) (<xref rid="B18" ref-type="bibr">18</xref>).</p></sec><sec id="s3c"><title>Late SND</title><p>Late onset SND has a reported incidence between 15% and 44% (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B79" ref-type="bibr">79</xref>). There is evidence that the presence of early SND predicts the development of late SND (<xref rid="B63" ref-type="bibr">63</xref>), and several studies have demonstrated that SND becomes more prevalent over time (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B80" ref-type="bibr">80</xref>). Any of the estimate of the incidence of SND likely underestimates the true frequency, given to the presence of asymptomatic patients.</p><p>Late SND associated with an APC Fontan has been reported in 10%&#x02013;12% of patients (<xref rid="B80" ref-type="bibr">80</xref>). As with early onset SND, multiple studies have compared the incidence of late SND associated with the ILT vs. ECC procedure. Dilawar et al. reported a higher frequency of SND after ECC over a seven-year period in 4/19 ILT patients (21%) vs. 10/17 ECC patients (59%; <italic>p</italic>&#x02009;=&#x02009;0.04) (<xref rid="B58" ref-type="bibr">58</xref>). However, this was a single-center retrospective study with longer mean follow-up in the ECC compared to the ILT group. In contrast, N&#x000fc;rnberg et al. found that late SND was higher in patients after ILT, with 50% of patients following ILT being in a non-sinus rhythm at follow up compared to 14% for ECC patients (<xref rid="B60" ref-type="bibr">60</xref>). However, in this study, the median follow up post-ECC was 4.4 years compared to 7.9 years for ILT (<xref rid="B60" ref-type="bibr">60</xref>). Overall, a majority of studies including multi-center studies and the meta-analysis from Li et al. have demonstrated no statistical difference in late SND between the two surgical approaches (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>).</p></sec><sec id="s3d"><title>Sinus node dysfunction or secondary limitation&#x02014;insights and the role of exercise testing</title><p>Multiple studies have shown that Fontan patients have an abnormal heart rate response to exercise. However, it is unclear if this is a primary rhythm problem or a secondary adaptive response. Powell et al. showed that in teenage Fontan patients, chronotropic limitation to exercise, as defined by chronotropic index [CI&#x02009;=&#x02009;actual peak heart rate (HR)&#x02014;resting HR/expected peak HR for age&#x02014;resting HR], was prevalent, with the mean CI being 0.72 as compared to a typical definition of chronotropic incompetence, which is a CI &#x0003c;0.8 (<xref rid="B81" ref-type="bibr">81</xref>). The CI, however, is an incomplete assessment of chronotropic function, as it only uses the peak HR (and not slope of HR change) and does not consider secondary reasons for peak HR truncation.</p><p>An alternative proposal is that in select Fontan patients, limitation in HR, especially during exercise, is a secondary and even adaptive phenomenon. Support for this comes from Claessen et al, who compared ten patients after Fontan palliation (mean age 20 years, 60% male) to healthy controls utilizing MRI and simultaneous invasive arterial pressure recording during exercise (<xref rid="B82" ref-type="bibr">82</xref>). Exercise associated cardiac index, stroke volume, and HR relative to peak oxygen consumption (VO2) were determined and compared amongst the groups. As expected, heart rate reserve (peak HR&#x02014;resting HR) was lower in Fontan patients compared to controls (71+/&#x02212;21 vs. 92+/&#x02212;15 bpm; <italic>p</italic>&#x02009;=&#x02009;0.01) (<xref rid="B82" ref-type="bibr">82</xref>). However, increase in HR relative to workload and peak VO2 were actually higher in the Fontan patients. Furthermore, the Fontan patients had reduced augmentation of stroke volume for any given change in VO2 (<xref rid="B82" ref-type="bibr">82</xref>). Finally, the Fontan patients had a pronounced plateau in cardiac output at a lower HR than controls (<xref rid="B82" ref-type="bibr">82</xref>). The authors concluded that HR response to exercise was actually appropriate relative to exercise intensity (implying lack of chronotropic incompetence). However, premature reduction in ventricular filling and thus stroke volume led to leveling off of cardiac output during exercise, thus making peak HR secondarily truncated (<xref rid="B82" ref-type="bibr">82</xref>). Hedlund et al. reported similar outcomes from their prospective cohort study. When comparing 27 teenage Fontan patients to healthy controls, the Fontan cohort's mean HR for any given workload was actually higher than the controls (<xref rid="B83" ref-type="bibr">83</xref>). Furthermore, oxygen pulse, a surrogate marker for stroke volume, was reduced at maximal effort in the Fontan patients comparatively (<xref rid="B83" ref-type="bibr">83</xref>). The authors postulated that this was related to reduced ability to augment stroke volume with more intensive exercise and thus the reduced HR was appropriate for the degree of stroke volume (<xref rid="B83" ref-type="bibr">83</xref>). Hebert et al. similarly concluded that low stroke volume index was the most important limiting factor for exercise capacity in Fontan patients (<xref rid="B84" ref-type="bibr">84</xref>). But how might this heart rate modulation actually occur? A proposal is that this occurs via the Bainbridge and &#x0201c;Reverse&#x0201d; Bainbridge reflexes. These reflexes are described within the anesthesia literature (<xref rid="B85" ref-type="bibr">85</xref>), given the HR changes that are routinely observed with changes in peri-procedural fluid status. Via stretch fibers near the vena cava and within the right atrium, excessive cardiac filling and overdistension is prevented via reflex tachycardia (in turn via inhibition of vagal outflow and enhancement of sympathetic stimulus to the sinus node). The &#x0201c;Reverse&#x0201d; Bainbridge is the opposite&#x02014;reduced venous return leads to deactivation of sinus node stimulation and in the midst of exercise, a negative stimulus for further HR elevation (<xref rid="B85" ref-type="bibr">85</xref>). In patients with worse Fontan hemodynamics (elevated central venous pressure and ventricular filling pressure), the already preload-deficient systemic ventricle (given the lack of a subpulmonary ventricle to augment pulmonary blood flow and thus pulmonary venous return to the heart) would be even more lacking in preload, thus leading to a lack of further stimulus to increase HR further during exercise (<xref rid="B85" ref-type="bibr">85</xref>).</p><p>Exercise testing is an excellent modality to utilize to help decipher whether HR limitation during exercise is primary or secondary to poor Fontan hemodynamics. In patients with primary sinus node dysfunction, heart rate during exercise would be expected to lag in general, and in comparison with oxygen consumption (VO2). Heart rate might even plateau prior to peak VO2 doing so (<xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref>). On the other hand, limitation in HR secondary to poor Fontan hemodynamics would be expected to show appropriate HR acceleration for any given increase in peak VO2, but abrupt truncation of HR at peak exercise rather than any plateau (<xref rid="F3" ref-type="fig">Figure&#x000a0;3</xref>). We believe complete evaluation of Fontan status, including exercise testing, has a role in deducing the etiology of HR limitation in a given patient and should be considered prior to pacemaker placement.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Example of relationship between heart rate and oxygen consumption during cardiopulmonary exercise test in patient with primary chronotropic incompetence.</p></caption><graphic xlink:href="fped-13-1506690-g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Example of relationship between heart rate and oxygen consumption during cardiopulmonary exercise test in patient with secondary limitation to heart rate such as poor fontan hemodynamics.</p></caption><graphic xlink:href="fped-13-1506690-g003" position="float"/></fig></sec><sec id="s3e"><title>Junctional rhythm</title><p>SND manifests as sinus bradycardia, pauses, and junctional rhythm (JR). JR can lead to asynchrony and loss of atrial kick, with further decrease in cardiac output (<xref rid="B86" ref-type="bibr">86</xref>). This is particularly important in the Fontan circulation given the tenuous hemodynamics present. JR is also often characterized by an insidious onset. Even more problematically, patients with JR may have a relatively normal heart rate which can further delay the recognition of this arrhythmia (<xref rid="B33" ref-type="bibr">33</xref>). An example of an ECG with JR in a Fontan patient is presented in <xref rid="F4" ref-type="fig">Figure&#x000a0;4</xref>. The frequency of JR after Fontan also tends to increase with time, with estimated incidence between 15% and 46% (<xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B87" ref-type="bibr">87</xref>). Furthermore, Januszewska et al. compared the rates of JR between the ILT and ECC. In this retrospective cohort study, ILT demonstrated significantly higher rates of JR early postoperatively (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), during hospitalization (<italic>p</italic>&#x02009;=&#x02009;0.004), and at discharge (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) (<xref rid="B87" ref-type="bibr">87</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p>12 lead of junctional rhythm in a fontan patient.</p></caption><graphic xlink:href="fped-13-1506690-g004" position="float"/></fig><p>Evidence for the deleterious effects of JR in the Fontan population comes from several studies. Ferrari et al. reported cardiac magnetic resonance-derived flow patterns showing retrograde flow in the entire Fontan system in a patient with JR (<xref rid="B88" ref-type="bibr">88</xref>). This flow reversal increases the pulmonary artery pressure, which in turn increases the hepatic and splanchnic venous pressures, which is particularly deleterious in the Fontan circulation (<xref rid="B89" ref-type="bibr">89</xref>). These studies suggest JR chronically decreases cardiac output and further elevates central venous pressure, known risk factors for developing Fontan failure (<xref rid="B54" ref-type="bibr">54</xref>). However, it is worth noting that each of these studies are either case reports or small series and the long-term impact of JR remains to be studied.</p><p>The optimal management of JR is unclear. In a recent survey of congenital cardiologists, 80% would not implant an atrial pacemaker in an asymptomatic patient with JR (<xref rid="B90" ref-type="bibr">90</xref>). On the other hand, more than 83% indicated that they would pursue pacemaker placement if the asymptomatic patient was already undergoing a sternotomy for another reason (<xref rid="B90" ref-type="bibr">90</xref>). This suggests that congenital cardiologists feel the risk of pacemaker placement is not worth the uncertain benefits to a patient with JR, although they also understand intuitively the possible benefit of treatment (<xref rid="B90" ref-type="bibr">90</xref>). There was general agreement that Fontan patients with symptomatic JR including evidence of Fontan failure should receive pacing, as 90% indicated they would support placement of a device (<xref rid="B90" ref-type="bibr">90</xref>).</p></sec><sec id="s3f"><title>Is pacing the solution for the bradycardic fontan?</title><p>The direct solution to managing significant bradycardia is pacing. The incidence of permanent pacemaker placement in the Fontan populations is 8%&#x02013;13% (<xref rid="B91" ref-type="bibr">91</xref>&#x02013;<xref rid="B93" ref-type="bibr">93</xref>). Additional reasons for placement following Fontan completion include anti-tachycardia management, ventricular tachycardia, and cardiac resynchronization (<xref rid="B92" ref-type="bibr">92</xref>).</p><p>There is evidence that permanent pacing is associated with clinical improvement and is recommended in symptomatic patients and those with exercise intolerance, or if there are hemodynamic derangements worsened by bradycardia (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B91" ref-type="bibr">91</xref>). Cohen et al. reported two patients in whom atrial pacing (AP) resolved symptoms of PLE (<xref rid="B94" ref-type="bibr">94</xref>). In these two patients, symptoms remained despite aggressive diuresis and creation of a fenestration in the Fontan circuit (<xref rid="B94" ref-type="bibr">94</xref>). In contrast, there was complete resolution of PLE within 6 weeks of AP (<xref rid="B1" ref-type="bibr">1</xref>). Heinemann et al. also reported improvement in PLE symptoms after placement of dual-chamber pacemakers in their case series (<xref rid="B95" ref-type="bibr">95</xref>). A separate report also described resolution of plastic bronchitis with AP (<xref rid="B96" ref-type="bibr">96</xref>). While this total experience is small, AP seems to offer Fontan patients clinical improvement when appropriately utilized.</p><p>Pacing has also been shown, via restoration of AV synchrony, to eliminate the reversal of fenestration flow, lower left atrial pressure, and improve cardiac output and clinical status in Fontan patients previously in junctional rhythm or undergoing ventricular pacing (<xref rid="B89" ref-type="bibr">89</xref>). In a recent study, Alnoor et al. reported 7 patients with Fontan physiology and JR undergoing cardiac catheterization (<xref rid="B97" ref-type="bibr">97</xref>). Hemodynamic measurements were performed in JR and during AP&#x0223c;10 beats faster than the JR rate. JR was associated with lower cardiac output and elevated central venous pressure, which improved with AP (<xref rid="B97" ref-type="bibr">97</xref>). AP increased CO (by&#x0223c;23%), from 2.7&#x02009;&#x000b1;&#x02009;0.8 (in JR) to 3.5&#x02009;&#x000b1;&#x02009;1&#x02005;L/min/m2 (<xref rid="B97" ref-type="bibr">97</xref>). AP also decreased left atrial pressure (from 8.8&#x02009;&#x000b1;&#x02009;2.6 to 5.5&#x02009;&#x000b1;&#x02009;2.9&#x02005;mmHg) and increased the pulmonary blood flow (<xref rid="B97" ref-type="bibr">97</xref>).</p><p>Not all studies, however, have shown a benefit to pacing. Ventricular pacing, in particular, seems to be problematic. A large Pediatric Heart Network study showed that ventricularly paced Fontan patients had worse clinical outcomes and decreased ventricular function compared to those who were not paced (<xref rid="B93" ref-type="bibr">93</xref>). Multiple studies have concluded that asynchronous ventricular pacing is particularly deleterious (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B98" ref-type="bibr">98</xref>&#x02013;<xref rid="B100" ref-type="bibr">100</xref>). Barber et al. found that systemic blood flow was significantly lower with VOO vs. AOO or DOO pacing and theorized that pacing from the ventricle leads to similar physiology to junctional rhythm, where the loss of synchrony leads to a loss of atrial kick (and thus decreased preload to the single ventricle and further reduction in stroke volume) (<xref rid="B91" ref-type="bibr">91</xref>). Poh et al. examined the Australian and New Zealand Fontan registry and demonstrated that amongst all paced patients, those with QRS interval &#x0003e;130&#x02005;ms on electrocardiogram were at greater risk of death and transplantation (<xref rid="B92" ref-type="bibr">92</xref>). Furthermore, they found that patients who had ventricular pacing &#x0003e;50% of the time were at higher risk of death, transplantation, and moderate to severe systemic ventricular dysfunction at latest follow-up (<xref rid="B92" ref-type="bibr">92</xref>). Poh also showed that atrial pacing was not associated with any of these deleterious effects (<xref rid="B92" ref-type="bibr">92</xref>).</p><p>Although there is evidence of benefit to AP in Fontan patients, pacemaker placement itself can be technically complex in this population. In ECC Fontan patients, where the conduit completely bypasses atrial tissue, lead placement requires a thoracotomy or other innovative approaches to reach the atria (<xref rid="B101" ref-type="bibr">101</xref>). Therefore, endocardial pacing (with transvenous leads to the atrium) often can only be accomplished in patients whom atrial tissue is present inside the Fontan circuit&#x02014;the APC or ILT Fontan. Endocardial leads also promote thrombus formation around the lead (which sits inside the sluggish and passive venous blood flow of the Fontan circulation) with embolization to the lungs or the systemic circulation being a possibility (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>). Given the more significant risk for morbidity and, potentially, mortality in this population, the decision to pace must be done with much thought and consideration.</p></sec><sec id="s3g"><title>Heart block</title><p>In single ventricle patients, who tend to be even more heart rate dependent (due to lack of a subpulmonary ventricle to aid preload to the systemic ventricle and thus stroke volume), it follows that heart block would be particularly poorly tolerated. NPC-QIC single-ventricle database studies have supported this, with reports of 39% mortality by 12 months of age in those with surgical heart block&#x02014;a more likely event compared to those single ventricle patients without heart block (OR 4.9, 95% GI 1.4&#x02013;17.5, <italic>p</italic>&#x02009;=&#x02009;0.01) (<xref rid="B104" ref-type="bibr">104</xref>). The resulting loss of atrioventricular synchrony is additionally problematic in Fontan patients, with studies showing association with increased hepatic pressures and clinical worsening (<xref rid="B89" ref-type="bibr">89</xref>). Chronic ventricular pacing has also been shown to be detrimental to single ventricle function over time. Bulic et al. evaluated 22 paced vs. 53 control (non-paced single ventricle) patients longitudinally in terms of clinical and echocardiographic parameter changes (<xref rid="B100" ref-type="bibr">100</xref>). The authors found that the paced patients were more likely to develop moderate to severe systolic dysfunction (68 vs. 15%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) and atrioventricular valve regurgitation (65 vs. 21%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) as well as require heart failure medications (65 vs. 21%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) or experience death or heart transplantation (odds ratio 4.9, 9% CI 1.05&#x02013;22.7, <italic>p</italic>&#x02009;=&#x02009;0.04) (<xref rid="B100" ref-type="bibr">100</xref>).</p><p>Histologic and pathologic causes for worsening ventricular function and outcomes in ventricularly paced patients have been described (<xref rid="B105" ref-type="bibr">105</xref>) and single ventricles with unique pressure and volume-loading challenges would seem at particular risk. To navigate this &#x0201c;rock and a hard place,&#x0201d; cardiac resynchronization therapy (CRT) has been proposed. Effectiveness, however, at least compared to in other patient populations, has not been extensively described. As an example, Dubin et al. reported that amongst 7 single-ventricle patients who underwent CRT/multisite resynchronization in their study, no significant improvement in systolic function was seen (<xref rid="B106" ref-type="bibr">106</xref>). Difficulties in understanding dyssynchrony in this patient population, as well as concrete issues such as exact location of lead placement, were postulated to be reasons for this lack of response (<xref rid="B106" ref-type="bibr">106</xref>). A larger review compared <italic>n</italic>&#x02009;=&#x02009;19 CRT paced Fontan patients vs. <italic>n</italic>&#x02009;=&#x02009;43 who were single-site ventricular paced (<xref rid="B19" ref-type="bibr">19</xref>). While there was no statistical difference in long-term outcomes, including ventricular systolic function and mortality, the authors acknowledged their study was likely underpowered to demonstrate the trend toward better outcomes in the CRT Fontans (<xref rid="B19" ref-type="bibr">19</xref>). Published guidelines including the 2021 PACES Expert Consensus Statement help with decision making in these complex patients (<xref rid="B107" ref-type="bibr">107</xref>). Pacing is a class I indication in patients with complex congenital heart disease with heart block resulting in hemodynamic compromise or a mean ventricular rate less than 60&#x02013;70&#x02005;bpm (<xref rid="B107" ref-type="bibr">107</xref>). This is a lower threshold than in patients without congenital heart disease, where a recommended mean ventricular rate &#x0003c;50&#x02005;bpm is advised (<xref rid="B107" ref-type="bibr">107</xref>). The expert panel notes the additional functional and structural lesions, as well as more easily compromised hemodynamics, as reasons behind this difference.</p></sec><sec id="s3h"><title>Monitoring and surveillance</title><p>There is little evidence to guide the frequency of monitoring for arrhythmias in Fontan patients. The 2019 American Heart Association guidelines recommend Holter monitoring every 2&#x02013;3 years in children and every 1&#x02013;2 years in adolescents and adults (<xref rid="B1" ref-type="bibr">1</xref>). However, the guidelines were not rooted in strong evidence and instead on the consensus of the authors (<xref rid="B1" ref-type="bibr">1</xref>). In a survey of centers with existing Fontan care programs, 27% obtain Holter monitoring annually while 36% of centers perform them every other year (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>Saley et al. conducted a retrospective review of their institutional Fontan ambulatory rhythm surveillance program to study its utility (<xref rid="B109" ref-type="bibr">109</xref>). The protocol included routine use of ambulatory rhythm monitors at ages 6, 10, 13, 16, and 19 years of age (<xref rid="B109" ref-type="bibr">109</xref>). Eighty-three patients were included in the study with a total of 134 unique studies. Routine surveillance was the indication for 56% of the studies, with the remainder ordered for an abnormal electrocardiogram (28%), prior arrhythmias (36%), or reported symptoms (36%) (<xref rid="B109" ref-type="bibr">109</xref>). Indicated studies were more likely to find arrhythmia than surveillance studies (52% vs. 26%, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) (<xref rid="B109" ref-type="bibr">109</xref>). Occult arrhythmias (not anticipated, found on surveillance studies) were responsible for 39% of positive ambulatory tests. The most common occult arrhythmia was SVT (10/23, 43%) with ventricular ectopy (9/23, 39%), accelerated junctional rhythm (3/23, 13%), and SND (1/23, 4%) also found (<xref rid="B109" ref-type="bibr">109</xref>). The most common arrhythmia on clinically indicated studies was accelerated junctional rhythm (15/45, 33%), with SVT (13/45, 29%), complex ventricular ectopy (11/45, 24%), Wenckebach rhythm (4/45, 9%), and SND (2/45, 4%) also being reported (<xref rid="B109" ref-type="bibr">109</xref>). Arrhythmia surveillance was increased in response to three (15%) studies with occult arrhythmias (1 SVT, 2 complex ventricular ectopy), and detection of any arrhythmia (occult or symptomatic) led to a change in clinical management in 31% of positive tests (14 patients with increased surveillance with the remaining two resulting in medications changes) (<xref rid="B109" ref-type="bibr">109</xref>).</p><p>Another study from Czosek et al. examined the utility of Holter monitoring in several different patient populations including those with Fontan physiology (<xref rid="B110" ref-type="bibr">110</xref>). Of the <italic>n</italic>&#x02009;=&#x02009;51 Fontan patients undergoing a total of 148 Holter studies, 79% of the studies were obtained in asymptomatic patients (<xref rid="B110" ref-type="bibr">110</xref>). Of this Fontan cohort, the researchers found that only 9 of the 148 (6%) Holters lead to a change in clinical management (<xref rid="B110" ref-type="bibr">110</xref>). Of these, 5 of the patients underwent electrophysiology studies, four received pacemakers, and one had an implantable cardioverter-defibrillator device placed (<xref rid="B110" ref-type="bibr">110</xref>). The study examined the predictive values of Holter monitoring for detection of a significant arrhythmia event, including SVT, VT, SCD, and a history of appropriate ICD device therapy. The positive predictive value was poor (8%), however the negative predictive value was high (94%) (<xref rid="B110" ref-type="bibr">110</xref>). The study did not comment on a suggested frequency of monitoring. As such, following reported guidelines remains reasonable for now, with the hope that further studies will better inform these decisions over time.</p></sec><sec sec-type="conclusions" id="s3i"><title>Conclusions</title><p>While the full scope of both the prevalence as well as the clinical implications of bradyarrhythmias in the Fontan population are still poorly defined, there is undoubtedly evidence that it is a common complication of the procedure and is likely underappreciated. Despite modifications to the Fontan procedure, arrythmias persist. It appears that the incidence of sinus node dysfunction increases as a function of time with many progressing to junctional rhythm. While pacing has been considered as a therapy for this patient population, the evidence to support this practice is inconclusive. Current guidelines recommend surveillance with Holter monitor every 2&#x02013;3 years in adolescents and every 1&#x02013;2 years in adults. Future directions for research include further assessment of junctional rhythm and its management as well as further identifying patients in which pacing would be beneficial.</p></sec></sec></body><back><sec sec-type="author-contributions" id="s11"><title>Author contributions</title><p>KW: Conceptualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. CH: Conceptualization, Supervision, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. RD: Conceptualization, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. SB: Conceptualization, Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s13"><title>Conflict of interest</title><p>SB is a consultant to Milestone pharmaceuticals and Tenaya pharmaceuticals.</p><p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s15"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s14"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rychik</surname><given-names>J</given-names></name><name><surname>Atz</surname><given-names>AM</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name><name><surname>Deal</surname><given-names>BJ</given-names></name><name><surname>Gatzoulis</surname><given-names>MA</given-names></name><name><surname>Gewillig</surname><given-names>MH</given-names></name><etal/></person-group>
<article-title>Evaluation and management of the child and adult with fontan circulation: a scientific statement from the American Heart Association</article-title>. <source>Circulation</source>. (<year>2019</year>) <volume>140</volume>(<issue>6</issue>):<fpage>e234</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000696</pub-id><pub-id pub-id-type="pmid">31256636</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deal</surname><given-names>BJ</given-names></name><name><surname>Mavroudis</surname><given-names>C</given-names></name><name><surname>Backer</surname><given-names>CL</given-names></name></person-group>. <article-title>Arrhythmia management in the fontan patient</article-title>. <source>Pediatr Cardiol</source>. (<year>2007</year>) <volume>28</volume>:<fpage>448</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-007-9005-2</pub-id><pub-id pub-id-type="pmid">17828373</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>CC</given-names></name><name><surname>Maldonado</surname><given-names>JR</given-names></name><name><surname>Olson</surname><given-names>MD</given-names></name><name><surname>Gingerich</surname><given-names>JC</given-names></name><name><surname>Ochoa</surname><given-names>LA</given-names></name><name><surname>Law</surname><given-names>IH</given-names></name></person-group>. <article-title>Atrial antitachycardia pacing in complex congenital heart disease: a case series</article-title>. <source>J Innov Card Rhythm Manag</source>. (<year>2018</year>) <volume>9</volume>(<issue>3</issue>):<fpage>3079</fpage>. <pub-id pub-id-type="doi">10.19102/icrm.2018.090304</pub-id><pub-id pub-id-type="pmid">32477803</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atallah</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>KK</given-names></name><name><surname>Jonas</surname><given-names>RA</given-names></name><name><surname>Mayer Jr</surname><given-names>JE</given-names></name><name><surname>Triedman</surname><given-names>JK</given-names></name></person-group>. <article-title>Follow-up of a modified fontan randomized trial for intraatrial reentrant tachycardia prophylaxis</article-title>. <source>Congenit Heart Dis</source>. (<year>2012</year>) <volume>7</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0803.2012.00636.x</pub-id><pub-id pub-id-type="pmid">22631077</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinton</surname><given-names>E</given-names></name><name><surname>Nightingale</surname><given-names>P</given-names></name><name><surname>Hudsmith</surname><given-names>L</given-names></name><name><surname>Thorne</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>H</given-names></name><name><surname>Clift</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Prevalence of atrial tachyarrhythmia in adults after fontan operation</article-title>. <source>Heart</source>. (<year>2015</year>) <volume>101</volume>(<issue>20</issue>):<fpage>1672</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2015-307514</pub-id><pub-id pub-id-type="pmid">26289423</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pundi</surname><given-names>KN</given-names></name><name><surname>Pundi</surname><given-names>KN</given-names></name><name><surname>Johnson</surname><given-names>JN</given-names></name><name><surname>Dearani</surname><given-names>JA</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Driscoll</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Sudden cardiac death and late arrhythmias after the fontan operation</article-title>. <source>Congenit Heart Dis</source>. (<year>2017</year>) <volume>12</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1111/chd.12401</pub-id><pub-id pub-id-type="pmid">27545004</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Zannino</surname><given-names>D</given-names></name><name><surname>du Plessis</surname><given-names>K</given-names></name><name><surname>Bullock</surname><given-names>A</given-names></name><name><surname>Disney</surname><given-names>PJ</given-names></name><name><surname>Radford</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Clinical outcomes in adolescents and adults after the fontan procedure</article-title>. <source>J Am Coll Cardiol</source>. (<year>2018</year>) <volume>71</volume>(<issue>9</issue>):<fpage>1009</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.12.054</pub-id><pub-id pub-id-type="pmid">29495980</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backer</surname><given-names>CL</given-names></name><name><surname>Mavroudis</surname><given-names>C</given-names></name></person-group>. <article-title>149 fontan conversions</article-title>. <source>Methodist Debakey Cardiovasc J</source>. (<year>2021</year>) <volume>15</volume>(<issue>2</issue>):<fpage>105</fpage>. <pub-id pub-id-type="doi">10.14797/mdcj-15-2-105</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poh</surname><given-names>CL</given-names></name><name><surname>Zannino</surname><given-names>D</given-names></name><name><surname>Weintraub</surname><given-names>RG</given-names></name><name><surname>Winlaw</surname><given-names>DS</given-names></name><name><surname>Grigg</surname><given-names>LE</given-names></name><name><surname>Cordina</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Three decades later: the fate of the population of patients who underwent the atriopulmonary fontan procedure</article-title>. <source>Int J Cardiol</source>. (<year>2017</year>) <volume>231</volume>:<fpage>99</fpage>&#x02013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2017.01.057</pub-id><pub-id pub-id-type="pmid">28100430</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rijnberg</surname><given-names>FM</given-names></name><name><surname>Blom</surname><given-names>NA</given-names></name><name><surname>Sojak</surname><given-names>V</given-names></name><name><surname>Bruggemans</surname><given-names>EF</given-names></name><name><surname>Kuipers</surname><given-names>IM</given-names></name><name><surname>Rammeloo</surname><given-names>LA</given-names></name><etal/></person-group>
<article-title>A 45-year experience with the fontan procedure: tachyarrhythmia, an important sign for adverse outcome</article-title>. <source>Interact Cardiovasc Thorac Surg</source>. (<year>2019</year>) <volume>29</volume>(<issue>3</issue>):<fpage>461</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/icvts/ivz111</pub-id><pub-id pub-id-type="pmid">31038168</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilner</surname><given-names>P</given-names></name><name><surname>de Leval</surname><given-names>M</given-names></name></person-group>. <article-title>A model to simulate the effects of right heart pulsatile flow after modified fontain procedure</article-title>. <source>Br Heart J</source>. (<year>1993</year>) <volume>69</volume>(<issue>1</issue>):<fpage>93</fpage>. <pub-id pub-id-type="doi">10.1136/hrt.69.1.93-a</pub-id><pub-id pub-id-type="pmid">8457405</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gewillig</surname><given-names>M</given-names></name><name><surname>Wyse</surname><given-names>RK</given-names></name><name><surname>de Leval</surname><given-names>MR</given-names></name><name><surname>Deanfield</surname><given-names>JE</given-names></name></person-group>. <article-title>Early and late arrhythmias after the fontan operation: predisposing factors and clinical consequences</article-title>. <source>Heart</source>. (<year>1992</year>) <volume>67</volume>(<issue>1</issue>):<fpage>72</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/hrt.67.1.72</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacone</surname><given-names>HM</given-names></name><name><surname>Chubb</surname><given-names>H</given-names></name><name><surname>Dubin</surname><given-names>AM</given-names></name><name><surname>Motonaga</surname><given-names>KS</given-names></name><name><surname>Ceresnak</surname><given-names>SR</given-names></name><name><surname>Goodyer</surname><given-names>WR</given-names></name><etal/></person-group>
<article-title>Outcomes after development of ventricular arrhythmias in single ventricular heart disease patients with fontan palliation</article-title>. <source>Circ Arrhythm Electrophysiol</source>. (<year>2023</year>) <volume>16</volume>(<issue>6</issue>):<fpage>e011143</fpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.122.011143</pub-id><pub-id pub-id-type="pmid">37254747</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcelletti</surname><given-names>CF</given-names></name><name><surname>Iorio</surname><given-names>FS</given-names></name><name><surname>Abella</surname><given-names>RF</given-names></name></person-group>. <article-title>Late results of extracardiac fontan repair</article-title>. <source>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</source>. (<year>1999</year>) <volume>2</volume>:<fpage>131</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/S1092-9126(99)70014-1</pub-id><pub-id pub-id-type="pmid">11486232</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathod</surname><given-names>RH</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Powell</surname><given-names>AJ</given-names></name><name><surname>Geva</surname><given-names>T</given-names></name></person-group>. <article-title>Myocardial fibrosis identified by cardiac magnetic resonance late gadolinium enhancement is associated with adverse ventricular mechanics and ventricular tachycardia late after fontan operation</article-title>. <source>J Am Coll Cardiol</source>. (<year>2010</year>) <volume>55</volume>(<issue>16</issue>):<fpage>1721</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2009.12.036</pub-id><pub-id pub-id-type="pmid">20394877</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diller</surname><given-names>GP</given-names></name><name><surname>Giardini</surname><given-names>A</given-names></name><name><surname>Dimopoulos</surname><given-names>K</given-names></name><name><surname>Gargiulo</surname><given-names>G</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>J</given-names></name><name><surname>Derrick</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Predictors of morbidity and mortality in contemporary fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients</article-title>. <source>Eur Heart J</source>. (<year>2010</year>) <volume>31</volume>(<issue>24</issue>):<fpage>3073</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehq356</pub-id><pub-id pub-id-type="pmid">20929979</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stout</surname><given-names>KK</given-names></name><name><surname>Daniels</surname><given-names>CJ</given-names></name><name><surname>Aboulhosn</surname><given-names>JA</given-names></name><name><surname>Bozkurt</surname><given-names>B</given-names></name><name><surname>Broberg</surname><given-names>CS</given-names></name><name><surname>Colman</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines</article-title>. <source>J Am Coll Cardiol</source>. (<year>2019</year>) <volume>73</volume>(<issue>12</issue>):<fpage>e81</fpage>&#x02013;<lpage>e192</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2018.08.1029</pub-id><pub-id pub-id-type="pmid">30121239</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>An</surname><given-names>Q</given-names></name></person-group>. <article-title>Arrhythmias after fontan operation with intra-atrial lateral tunnel versus extra-cardiac conduit: a systematic review and meta-analysis</article-title>. <source>Pediatr Cardiol</source>. (<year>2017</year>) <volume>38</volume>:<fpage>873</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-017-1595-8</pub-id><pub-id pub-id-type="pmid">28271152</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Leary</surname><given-names>ET</given-names></name><name><surname>Gauvreau</surname><given-names>K</given-names></name><name><surname>Alexander</surname><given-names>ME</given-names></name><name><surname>Banka</surname><given-names>P</given-names></name><name><surname>Bezzerides</surname><given-names>VJ</given-names></name><name><surname>Fynn-Thompson</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Dual-site ventricular pacing in patients with fontan physiology and heart block: does it mitigate the detrimental effects of single-site ventricular pacing?</article-title>
<source>JACC Clin Electrophysiol</source>. (<year>2018</year>) <volume>4</volume>(<issue>10</issue>):<fpage>1289</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacep.2018.07.004</pub-id><pub-id pub-id-type="pmid">30336874</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>An</surname><given-names>Q</given-names></name></person-group>. <article-title>Comparison of the fenestrated and non-fenestrated fontan procedures: a meta-analysis</article-title>. <source>Medicine (Baltimore)</source>. (<year>2019</year>) <volume>98</volume>(<issue>29</issue>):<fpage>e16554</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000016554</pub-id><pub-id pub-id-type="pmid">31335738</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>BM</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><name><surname>Nisbet</surname><given-names>AM</given-names></name><name><surname>Kalla</surname><given-names>M</given-names></name><name><surname>du Plessis</surname><given-names>K</given-names></name><name><surname>d&#x02019;Udekem</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Ablation of atrial arrhythmias after the atriopulmonary fontan procedure: mechanisms of arrhythmia and outcomes</article-title>. <source>JACC</source>. (<year>2018</year>) <volume>4</volume>(<issue>10</issue>):<fpage>1338</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacep.2018.08.012</pub-id><pub-id pub-id-type="pmid">30336880</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laubham</surname><given-names>M</given-names></name><name><surname>Blais</surname><given-names>B</given-names></name><name><surname>Kamp</surname><given-names>AN</given-names></name></person-group>. <article-title>Atrial arrhythmias in adults with fontan palliation</article-title>. <source>Cardiol Ther</source>. (<year>2023</year>) <volume>12</volume>(<issue>3</issue>):<fpage>473</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1007/s40119-023-00326-5</pub-id><pub-id pub-id-type="pmid">37495769</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>EA</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name><name><surname>Etheridge</surname><given-names>SP</given-names></name><name><surname>Idriss</surname><given-names>SF</given-names></name><name><surname>Margossian</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Arrhythmias in a contemporary fontan cohort: prevalence and clinical associations in a multicenter cross-sectional study</article-title>. <source>J Am Coll Cardiol</source>. (<year>2010</year>) <volume>56</volume>(<issue>11</issue>):<fpage>890</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2010.03.079</pub-id><pub-id pub-id-type="pmid">20813285</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannakoulas</surname><given-names>G</given-names></name><name><surname>Dimopoulos</surname><given-names>K</given-names></name><name><surname>Yuksel</surname><given-names>S</given-names></name><name><surname>Inuzuka</surname><given-names>R</given-names></name><name><surname>Pijuan-Domenech</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Atrial tachyarrhythmias late after fontan operation are related to increase in mortality and hospitalization</article-title>. <source>Int J Cardiol</source>. (<year>2012</year>) <volume>157</volume>(<issue>2</issue>):<fpage>221</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2010.12.049</pub-id><pub-id pub-id-type="pmid">21196055</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d&#x02019;Udekem</surname><given-names>Y</given-names></name><name><surname>Iyengar</surname><given-names>AJ</given-names></name><name><surname>Galati</surname><given-names>JC</given-names></name><name><surname>Forsdick</surname><given-names>V</given-names></name><name><surname>Weintraub</surname><given-names>RG</given-names></name><name><surname>Wheaton</surname><given-names>GR</given-names></name><etal/></person-group>
<article-title>Redefining expectations of long-term survival after the fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand</article-title>. <source>Circulation</source>. (<year>2014</year>) <volume>130</volume>(<issue>11_suppl_1</issue>):<fpage>S32</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.007764</pub-id><pub-id pub-id-type="pmid">25200053</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Comparison of extracardiac conduit and lateral tunnel for functional single-ventricle patients: a meta-analysis</article-title>. <source>Congenit Heart Dis</source>. (<year>2017</year>) <volume>12</volume>(<issue>6</issue>):<fpage>711</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/chd.12503</pub-id><pub-id pub-id-type="pmid">28845580</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossers</surname><given-names>SS</given-names></name><name><surname>Duppen</surname><given-names>N</given-names></name><name><surname>Kapusta</surname><given-names>L</given-names></name><name><surname>Maan</surname><given-names>AC</given-names></name><name><surname>Duim</surname><given-names>AR</given-names></name><name><surname>Bogers</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Comprehensive rhythm evaluation in a large contemporary fontan population</article-title>. <source>Eur J Cardiothorac Surg</source>. (<year>2015</year>) <volume>48</volume>(<issue>6</issue>):<fpage>833</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1093/ejcts/ezu548</pub-id><pub-id pub-id-type="pmid">25602059</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atz</surname><given-names>AM</given-names></name><name><surname>Zak</surname><given-names>V</given-names></name><name><surname>Mahony</surname><given-names>L</given-names></name><name><surname>Uzark</surname><given-names>K</given-names></name><name><surname>D&#x02019;agincourt</surname><given-names>N</given-names></name><name><surname>Goldberg</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Longitudinal outcomes of patients with single ventricle after the fontan procedure</article-title>. <source>J Am Coll Cardiol</source>. (<year>2017</year>) <volume>69</volume>(<issue>22</issue>):<fpage>2735</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2017.03.582</pub-id><pub-id pub-id-type="pmid">28571639</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Mambro</surname><given-names>C</given-names></name><name><surname>Yammine</surname><given-names>ML</given-names></name><name><surname>Tamborrino</surname><given-names>PP</given-names></name><name><surname>Giordano</surname><given-names>U</given-names></name><name><surname>Righi</surname><given-names>D</given-names></name><name><surname>Unolt</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Long-term incidence of arrhythmias in extracardiac conduit fontan and comparison between systemic left and right ventricle</article-title>. <source>Europace</source>. (<year>2024</year>) <volume>26</volume>(<issue>5</issue>):<fpage>euae097</fpage>. <pub-id pub-id-type="doi">10.1093/europace/euae097</pub-id><pub-id pub-id-type="pmid">38650062</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durongpisitkul</surname><given-names>K</given-names></name><name><surname>Porter</surname><given-names>CBJ</given-names></name><name><surname>Cetta</surname><given-names>F</given-names></name><name><surname>Offord</surname><given-names>KP</given-names></name><name><surname>Slezak</surname><given-names>JM</given-names></name><name><surname>Puga</surname><given-names>FJ</given-names></name><etal/></person-group>
<article-title>Predictors of early-and late-onset supraventricular tachyarrhythmias after fontan operation</article-title>. <source>Circulation</source>. (<year>1998</year>) <volume>98</volume>(<issue>11</issue>):<fpage>1099</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.98.11.1099</pub-id><pub-id pub-id-type="pmid">9736597</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohuchi</surname><given-names>H</given-names></name></person-group>. <article-title>Adult patients with fontan circulation: what we know and how to manage adults with fontan circulation?</article-title>
<source>J Cardiol</source>. (<year>2016</year>) <volume>68</volume>(<issue>3</issue>):<fpage>181</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jjcc.2016.04.001</pub-id><pub-id pub-id-type="pmid">27134136</pub-id>
</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000fc;rer</surname><given-names>CC</given-names></name><name><surname>Tanner</surname><given-names>CS</given-names></name><name><surname>Vetter</surname><given-names>VL</given-names></name></person-group>. <article-title>Electrophysiologic findings after fontan repair of functional single ventricle</article-title>. <source>J Am Coll Cardiol</source>. (<year>1991</year>) <volume>17</volume>(<issue>1</issue>):<fpage>174</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/0735-1097(91)90723-M</pub-id><pub-id pub-id-type="pmid">1987223</pub-id>
</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carins</surname><given-names>TA</given-names></name><name><surname>Shi</surname><given-names>WY</given-names></name><name><surname>Iyengar</surname><given-names>AJ</given-names></name><name><surname>Nisbet</surname><given-names>A</given-names></name><name><surname>Forsdick</surname><given-names>V</given-names></name><name><surname>Zannino</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Long-term outcomes after first-onset arrhythmia in fontan physiology</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2016</year>) <volume>152</volume>(<issue>5</issue>):<fpage>1355</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2016.07.073</pub-id><pub-id pub-id-type="pmid">27751239</pub-id>
</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>D</given-names></name><name><surname>Toyohara</surname><given-names>K</given-names></name><name><surname>Kudo</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Shoda</surname><given-names>M</given-names></name></person-group>. <article-title>Impact of preoperative electrophysiological intervention on occurrence of peri/postoperative supraventricular tachycardia following fontan surgery</article-title>. <source>Heart Rhythm</source>. (<year>2021</year>) <volume>18</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2020.08.003</pub-id><pub-id pub-id-type="pmid">32781159</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khairy</surname><given-names>P</given-names></name><name><surname>Van Hare</surname><given-names>GF</given-names></name><name><surname>Balaji</surname><given-names>S</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name><name><surname>Cecchin</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>MI</given-names></name><etal/></person-group>
<article-title>PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the pediatric and congenital electrophysiology society (PACES) and the heart rhythm society (HRS). endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European heart rhythm association (EHRA), the Canadian heart rhythm society (CHRS), and the international society for adult</article-title>. <source>Heart Rhythm</source>. (<year>2014</year>) <volume>11</volume>(<issue>10</issue>):<fpage>e102</fpage>&#x02013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2014.05.009</pub-id><pub-id pub-id-type="pmid">24814377</pub-id>
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egbe</surname><given-names>AC</given-names></name><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Khan</surname><given-names>AR</given-names></name><name><surname>Niaz</surname><given-names>T</given-names></name><name><surname>Said</surname><given-names>SS</given-names></name><name><surname>Dearani</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Outcomes in adult fontan patients with atrial tachyarrhythmias</article-title>. <source>Am Heart J</source>. (<year>2017</year>) <volume>186</volume>:<fpage>12</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2016.12.015</pub-id><pub-id pub-id-type="pmid">28454826</pub-id>
</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyak</surname><given-names>Z</given-names></name><name><surname>Kroon</surname><given-names>B</given-names></name><name><surname>de Groot</surname><given-names>JR</given-names></name><name><surname>Wagenaar</surname><given-names>LJ</given-names></name><name><surname>van Dijk</surname><given-names>AP</given-names></name><name><surname>Mulder</surname><given-names>BA</given-names></name><etal/></person-group>
<article-title>Efficacy of antiarrhythmic drugs in adults with congenital heart disease and supraventricular tachycardias</article-title>. <source>Am J Cardiol</source>. (<year>2013</year>) <volume>112</volume>(<issue>9</issue>):<fpage>1461</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2013.07.029</pub-id><pub-id pub-id-type="pmid">23993125</pub-id>
</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egbe</surname><given-names>AC</given-names></name><name><surname>Asirvatham</surname><given-names>SJ</given-names></name><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Kapa</surname><given-names>S</given-names></name><name><surname>Desimone</surname><given-names>CV</given-names></name><name><surname>Vaidya</surname><given-names>VR</given-names></name><etal/></person-group>
<article-title>Outcomes of direct current cardioversion in adults with congenital heart disease</article-title>. <source>Am J Cardiol</source>. (<year>2017</year>) <volume>119</volume>(<issue>9</issue>):<fpage>1468</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2017.01.018</pub-id><pub-id pub-id-type="pmid">28262200</pub-id>
</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egbe</surname><given-names>AC</given-names></name><name><surname>Connolly</surname><given-names>HM</given-names></name><name><surname>Niaz</surname><given-names>T</given-names></name><name><surname>McLeod</surname><given-names>CJ</given-names></name></person-group>. <article-title>Outcome of direct current cardioversion for atrial arrhythmia in adult fontan patients</article-title>. <source>Int J Cardiol</source>. (<year>2016</year>) <volume>208</volume>:<fpage>115</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2016.01.209</pub-id><pub-id pub-id-type="pmid">26849685</pub-id>
</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebe</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>P</given-names></name><name><surname>Ouyang</surname><given-names>F</given-names></name><name><surname>Volkmer</surname><given-names>M</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name></person-group>. <article-title>Radiofrequency catheter ablation of tachycardia in patients with congenital heart disease</article-title>. <source>Pediatr Cardiol</source>. (<year>2000</year>) <volume>21</volume>:<fpage>557</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1007/s002460010134</pub-id><pub-id pub-id-type="pmid">11050280</pub-id>
</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weipert</surname><given-names>J</given-names></name><name><surname>Noebauer</surname><given-names>C</given-names></name><name><surname>Schreiber</surname><given-names>C</given-names></name><name><surname>Kostolny</surname><given-names>M</given-names></name><name><surname>Zrenner</surname><given-names>B</given-names></name><name><surname>Wacker</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Occurrence and management of atrial arrhythmia after long-term fontan circulation</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2004</year>) <volume>127</volume>(<issue>2</issue>):<fpage>457</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2003.08.054</pub-id><pub-id pub-id-type="pmid">14762355</pub-id>
</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>R</given-names></name><name><surname>Sherwin</surname><given-names>ED</given-names></name><name><surname>Kovach</surname><given-names>J</given-names></name><name><surname>Mah</surname><given-names>DY</given-names></name><name><surname>Alexander</surname><given-names>ME</given-names></name><name><surname>Cecchin</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Mechanism and ablation of arrhythmia following total cavopulmonary connection</article-title>. <source>Circ Arrhythm Electrophysiol</source>. (<year>2015</year>) <volume>8</volume>(<issue>2</issue>):<fpage>318</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.114.001758</pub-id><pub-id pub-id-type="pmid">25583982</pub-id>
</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radbill</surname><given-names>AE</given-names></name><name><surname>Triedman</surname><given-names>JK</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name><name><surname>Fynn-Thompson</surname><given-names>F</given-names></name><name><surname>Atallah</surname><given-names>J</given-names></name><name><surname>Alexander</surname><given-names>ME</given-names></name><etal/></person-group>
<article-title>System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients</article-title>. <source>Heart Rhythm</source>. (<year>2010</year>) <volume>7</volume>(<issue>2</issue>):<fpage>193</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2009.10.014</pub-id><pub-id pub-id-type="pmid">20022820</pub-id>
</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nery</surname><given-names>PB</given-names></name><name><surname>Green</surname><given-names>MS</given-names></name><name><surname>Khairy</surname><given-names>P</given-names></name><name><surname>Alhebaishi</surname><given-names>Y</given-names></name><name><surname>Hendry</surname><given-names>P</given-names></name><name><surname>Birnie</surname><given-names>DH</given-names></name></person-group>. <article-title>Implantable cardioverter-defibrillator insertion in congenital heart disease without transvenous access to the heart</article-title>. <source>Can J Cardiol</source>. (<year>2013</year>) <volume>29</volume>(<issue>2</issue>):<fpage>254</fpage>&#x02013;<lpage>e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2012.04.020</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chubb</surname><given-names>H</given-names></name><name><surname>Rosenthal</surname><given-names>E</given-names></name></person-group>. <article-title>Implantable cardioverter-defibrillators in congenital heart disease</article-title>. <source>Herzschrittmacherther Elektrophysiol</source>. (<year>2016</year>) <volume>27</volume>(<issue>2</issue>):<fpage>95</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1007/s00399-016-0437-3</pub-id><pub-id pub-id-type="pmid">27250725</pub-id>
</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>BC</given-names></name><name><surname>Friedman</surname><given-names>RA</given-names></name><name><surname>Fenrich</surname><given-names>AL</given-names></name><name><surname>Fraser</surname><given-names>CD</given-names></name><name><surname>McKENZIE</surname><given-names>ED</given-names></name><name><surname>Kertesz</surname><given-names>NJ</given-names></name></person-group>. <article-title>Innovative techniques for placement of implantable cardioverter-defibrillator leads in patients with limited venous access to the heart</article-title>. <source>Pacing Clin Electrophysiol</source>. (<year>2006</year>) <volume>29</volume>(<issue>2</issue>):<fpage>181</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1540-8159.2006.00314.x</pub-id><pub-id pub-id-type="pmid">16492305</pub-id>
</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Mond&#x000e9;sert</surname><given-names>B</given-names></name><name><surname>Lloyd</surname><given-names>MS</given-names></name><name><surname>Cook</surname><given-names>SC</given-names></name><name><surname>Zaidi</surname><given-names>AN</given-names></name><name><surname>Pass</surname><given-names>RH</given-names></name><etal/></person-group>
<article-title>Clinical experience with the subcutaneous implantable cardioverter&#x02013;defibrillator in adults with congenital heart disease</article-title>. <source>Circ Arrhythm Electrophysiol</source>. (<year>2016</year>) <volume>9</volume>(<issue>9</issue>):<fpage>e004338</fpage>. <pub-id pub-id-type="doi">10.1161/CIRCEP.116.004338</pub-id><pub-id pub-id-type="pmid">27635073</pub-id>
</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>A</given-names></name><name><surname>Ohuchi</surname><given-names>H</given-names></name><name><surname>Kurosaki</surname><given-names>KI</given-names></name><name><surname>Kamakura</surname><given-names>S</given-names></name><name><surname>Yagihara</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>O</given-names></name></person-group>. <article-title>Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease</article-title>. <source>Circ J</source>. (<year>2008</year>) <volume>72</volume>(<issue>12</issue>):<fpage>1998</fpage>&#x02013;<lpage>2003</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-08-0194</pub-id><pub-id pub-id-type="pmid">18931451</pub-id>
</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>MA</given-names></name><name><surname>Kerndt</surname><given-names>CC</given-names></name><name><surname>Tivakaran</surname><given-names>VS</given-names></name></person-group>. <article-title>Dofetilide</article-title>. (<year>2017</year>).</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>BM</given-names></name><name><surname>Cordina</surname><given-names>RL</given-names></name><name><surname>McGuire</surname><given-names>MA</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name></person-group>. <article-title>Adverse effects of amiodarone therapy in adults with congenital heart disease</article-title>. <source>Congenit Heart Dis</source>. (<year>2018</year>) <volume>13</volume>(<issue>6</issue>):<fpage>944</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/chd.12657</pub-id><pub-id pub-id-type="pmid">30239160</pub-id>
</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mavroudis</surname><given-names>C</given-names></name><name><surname>Deal</surname><given-names>BJ</given-names></name><name><surname>Backer</surname><given-names>CL</given-names></name><name><surname>Stewart</surname><given-names>RD</given-names></name><name><surname>Franklin</surname><given-names>WH</given-names></name><name><surname>Tsao</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>111 fontan conversions with arrhythmia surgery: surgical lessons and outcomes</article-title>. <source>Ann Thorac Surg</source>. (<year>2007</year>) <volume>84</volume>(<issue>5</issue>):<fpage>1457</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2007.06.079</pub-id><pub-id pub-id-type="pmid">17954046</pub-id>
</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deal</surname><given-names>BJ</given-names></name><name><surname>Costello</surname><given-names>JM</given-names></name><name><surname>Webster</surname><given-names>G</given-names></name><name><surname>Tsao</surname><given-names>S</given-names></name><name><surname>Backer</surname><given-names>CL</given-names></name><name><surname>Mavroudis</surname><given-names>C</given-names></name></person-group>. <article-title>Intermediate-term outcome of 140 consecutive fontan conversions with arrhythmia operations</article-title>. <source>Ann Thorac Surg</source>. (<year>2016</year>) <volume>101</volume>(<issue>2</issue>):<fpage>717</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2015.09.017</pub-id><pub-id pub-id-type="pmid">26602004</pub-id>
</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khairy</surname><given-names>P</given-names></name><name><surname>Fernandes</surname><given-names>SM</given-names></name><name><surname>Mayer</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Triedman</surname><given-names>JK</given-names></name><name><surname>Walsh</surname><given-names>EP</given-names></name><name><surname>Lock</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Long-term survival, modes of death, and predictors of mortality in patients with fontan surgery</article-title>. <source>Circulation</source>. (<year>2008</year>) <volume>117</volume>(<issue>1</issue>):<fpage>85</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.738559</pub-id><pub-id pub-id-type="pmid">18071068</pub-id>
</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van De Bruaene</surname><given-names>A</given-names></name><name><surname>Claessen</surname><given-names>G</given-names></name><name><surname>Salaets</surname><given-names>T</given-names></name><name><surname>Gewillig</surname><given-names>M</given-names></name></person-group>. <article-title>Late fontan circulatory failure. What drives systemic venous congestion and low cardiac output in adult fontan patients?</article-title><source>. Frontiers in Cardiovascular Medicine</source>. (<year>2022</year>) <volume>9</volume>:<fpage>825472</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.825472</pub-id><pub-id pub-id-type="pmid">35360011</pub-id>
</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon-Walker</surname><given-names>TT</given-names></name><name><surname>Bove</surname><given-names>K</given-names></name><name><surname>Veldtman</surname><given-names>G</given-names></name></person-group>. <article-title>Fontan-associated liver disease: a review</article-title>. <source>J Cardiol</source>. (<year>2019</year>) <volume>74</volume>(<issue>3</issue>):<fpage>223</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.jjcc.2019.02.016</pub-id><pub-id pub-id-type="pmid">30928109</pub-id>
</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Noh</surname><given-names>CI</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group>. <article-title>Sinus node dysfunction after fontan modifications&#x02014;influence of surgical method</article-title>. <source>Int J Cardiol</source>. (<year>2003</year>) <volume>88</volume>(<issue>2-3</issue>):<fpage>285</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/S0167-5273(02)00530-2</pub-id><pub-id pub-id-type="pmid">12714209</pub-id>
</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaufox</surname><given-names>AD</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Bradley</surname><given-names>DJ</given-names></name><name><surname>Breitbart</surname><given-names>RE</given-names></name><name><surname>Hordof</surname><given-names>A</given-names></name><name><surname>Kanter</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Functional status, heart rate, and rhythm abnormalities in 521 fontan patients 6 to 18 years of age</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2008</year>) <volume>136</volume>(<issue>1</issue>):<fpage>100</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2007.12.024</pub-id><pub-id pub-id-type="pmid">18603061</pub-id>
</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilawar</surname><given-names>M</given-names></name><name><surname>Bradley</surname><given-names>SM</given-names></name><name><surname>Saul</surname><given-names>JP</given-names></name><name><surname>Stroud</surname><given-names>MR</given-names></name><name><surname>Balaji</surname><given-names>S</given-names></name></person-group>. <article-title>Sinus node dysfunction after intraatrial lateral tunnel and extracardiac conduit fontan procedures: a study of 24-hour holter recordings</article-title>. <source>Pediatr Cardiol</source>. (<year>2003</year>) <volume>24</volume>(<issue>3</issue>):<fpage>284</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-002-0238-9</pub-id><pub-id pub-id-type="pmid">12522657</pub-id>
</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>SP</given-names></name><name><surname>Rubinstein</surname><given-names>CS</given-names></name><name><surname>Simsic</surname><given-names>JM</given-names></name><name><surname>Taylor</surname><given-names>AB</given-names></name><name><surname>Saul</surname><given-names>JP</given-names></name><name><surname>Bradley</surname><given-names>SM</given-names></name></person-group>. <article-title>Lateral tunnel versus extracardiac conduit fontan procedure: a concurrent comparison</article-title>. <source>Ann Thorac Surg</source>. (<year>2003</year>) <volume>76</volume>(<issue>5</issue>):<fpage>1389</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/S0003-4975(03)01010-5</pub-id><pub-id pub-id-type="pmid">14602257</pub-id>
</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000fc;rnberg</surname><given-names>JH</given-names></name><name><surname>Ovroutski</surname><given-names>S</given-names></name><name><surname>Alexi-Meskishvili</surname><given-names>V</given-names></name><name><surname>Ewert</surname><given-names>P</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name><name><surname>Lange</surname><given-names>PE</given-names></name></person-group>. <article-title>New onset arrhythmias after the extracardiac conduit fontan operation compared with the intraatrial lateral tunnel procedure: early and midterm results</article-title>. <source>Ann Thorac Surg</source>. (<year>2004</year>) <volume>78</volume>(<issue>6</issue>):<fpage>1979</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2004.02.107</pub-id><pub-id pub-id-type="pmid">15561013</pub-id>
</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ok&#x000f3;lska</surname><given-names>M</given-names></name><name><surname>Karkowski</surname><given-names>G</given-names></name><name><surname>Kuniewicz</surname><given-names>M</given-names></name><name><surname>Bednarek</surname><given-names>J</given-names></name><name><surname>Paj&#x00105;k</surname><given-names>J</given-names></name><name><surname>R&#x000f3;g</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Prevalence of arrhythmia in adults after fontan operation</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>(<issue>7</issue>):<fpage>1968</fpage>. <pub-id pub-id-type="doi">10.3390/jcm11071968</pub-id><pub-id pub-id-type="pmid">35407577</pub-id>
</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishberger</surname><given-names>SB</given-names></name><name><surname>Wernovsky</surname><given-names>G</given-names></name><name><surname>Gentles</surname><given-names>TL</given-names></name><name><surname>Gauvreau</surname><given-names>K</given-names></name><name><surname>Burnetta</surname><given-names>J</given-names></name><name><surname>Mayer Jr</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Factors that influence the development of atrial flutter after the fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>1997</year>) <volume>113</volume>(<issue>1</issue>):<fpage>80</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5223(97)70402-1</pub-id><pub-id pub-id-type="pmid">9011705</pub-id>
</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>MI</given-names></name><name><surname>Wernovsky</surname><given-names>G</given-names></name><name><surname>Vetter</surname><given-names>VL</given-names></name><name><surname>Wieand</surname><given-names>TS</given-names></name><name><surname>Gaynor</surname><given-names>JW</given-names></name><name><surname>Jacobs</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Sinus node function after a systematically staged fontan procedure</article-title>. <source>Circulation</source>. (<year>1998</year>) <volume>98</volume>(<issue>19 Suppl</issue>):<fpage>II352</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9852926</pub-id>
</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulfer</surname><given-names>K</given-names></name><name><surname>Bossers</surname><given-names>SS</given-names></name><name><surname>Utens</surname><given-names>EM</given-names></name><name><surname>Duppen</surname><given-names>N</given-names></name><name><surname>Kuipers</surname><given-names>IM</given-names></name><name><surname>Kapusta</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Does functional health status predict health-related quality of life in children after fontan operation?</article-title>
<source>Cardiol Young</source>. (<year>2016</year>) <volume>26</volume>(<issue>3</issue>):<fpage>459</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1017/S1047951115000426</pub-id><pub-id pub-id-type="pmid">25906441</pub-id>
</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amodeo</surname><given-names>A</given-names></name><name><surname>Galletti</surname><given-names>L</given-names></name><name><surname>Marianeschi</surname><given-names>S</given-names></name><name><surname>Picardo</surname><given-names>S</given-names></name><name><surname>Giannico</surname><given-names>S</given-names></name><name><surname>Di Renzi</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Extracardiac fontan operation for complex cardiac anomalies: seven years&#x02019; experience</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>1997</year>) <volume>114</volume>(<issue>6</issue>):<fpage>1020</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5223(97)70016-3</pub-id><pub-id pub-id-type="pmid">9434697</pub-id>
</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrossian</surname><given-names>ED</given-names></name><name><surname>Reddy</surname><given-names>VM</given-names></name><name><surname>McElhinney</surname><given-names>DB</given-names></name><name><surname>Akkersdijk</surname><given-names>GP</given-names></name><name><surname>Moore</surname><given-names>P</given-names></name><name><surname>Parry</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Early results of the extracardiac conduit fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>1999</year>) <volume>117</volume>(<issue>4</issue>):<fpage>688</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5223(99)70288-6</pub-id><pub-id pub-id-type="pmid">10096963</pub-id>
</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannico</surname><given-names>S</given-names></name><name><surname>Hammad</surname><given-names>F</given-names></name><name><surname>Amodeo</surname><given-names>A</given-names></name><name><surname>Michielon</surname><given-names>G</given-names></name><name><surname>Drago</surname><given-names>F</given-names></name><name><surname>Turchetta</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Clinical outcome of 193 extracardiac fontan patients: the first 15 years</article-title>. <source>J Am Coll Cardiol</source>. (<year>2006</year>) <volume>47</volume>(<issue>10</issue>):<fpage>2065</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2005.12.065</pub-id><pub-id pub-id-type="pmid">16697327</pub-id>
</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JR</given-names></name><name><surname>Kwak</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>KC</given-names></name><name><surname>Min</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>WH</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><etal/></person-group>
<article-title>Comparison of lateral tunnel and extracardiac conduit fontan procedure</article-title>. <source>Interact Cardiovasc Thorac Surg</source>. (<year>2007</year>) <volume>6</volume>(<issue>3</issue>):<fpage>328</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1510/icvts.2006.146928</pub-id><pub-id pub-id-type="pmid">17669857</pub-id>
</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajanbabu</surname><given-names>BB</given-names></name><name><surname>Gangopadhyay</surname><given-names>D</given-names></name></person-group>. <article-title>Sinus node dysfunction after extracardiac conduit and lateral tunnel fontan operation: the importance of the type of prior superior cavopulmonary anastomosis</article-title>. <source>World J Pediatr Congenit Heart Surg</source>. (<year>2016</year>) <volume>7</volume>(<issue>2</issue>):<fpage>210</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1177/2150135115616370</pub-id><pub-id pub-id-type="pmid">26957405</pub-id>
</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>MI</given-names></name><name><surname>Bridges</surname><given-names>ND</given-names></name><name><surname>Gaynor</surname><given-names>JW</given-names></name><name><surname>Hoffman</surname><given-names>TM</given-names></name><name><surname>Wernovsky</surname><given-names>G</given-names></name><name><surname>Vetter</surname><given-names>VL</given-names></name><etal/></person-group>
<article-title>Modifications to the cavopulmonary anastomosis do not eliminate early sinus node dysfunction</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2000</year>) <volume>120</volume>(<issue>5</issue>):<fpage>891</fpage>&#x02013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1067/mtc.2000.109708</pub-id><pub-id pub-id-type="pmid">11044315</pub-id>
</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balaji</surname><given-names>S</given-names></name><name><surname>Daga</surname><given-names>A</given-names></name><name><surname>Bradley</surname><given-names>DJ</given-names></name><name><surname>Etheridge</surname><given-names>SP</given-names></name><name><surname>Law</surname><given-names>IH</given-names></name><name><surname>Batra</surname><given-names>AS</given-names></name><etal/></person-group>
<article-title>An international multicenter study comparing arrhythmia prevalence between the intracardiac lateral tunnel and the extracardiac conduit type of fontan operations</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2014</year>) <volume>148</volume>(<issue>2</issue>):<fpage>576</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtcvs.2013.08.070</pub-id><pub-id pub-id-type="pmid">24172692</pub-id>
</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JW</given-names></name><name><surname>Ruzmetov</surname><given-names>M</given-names></name><name><surname>Deschner</surname><given-names>BW</given-names></name><name><surname>Rodefeld</surname><given-names>MD</given-names></name><name><surname>Turrentine</surname><given-names>MW</given-names></name></person-group>. <article-title>Lateral tunnel fontan in the current era: is it still a good option?</article-title>
<source>Ann Thorac Surg</source>. (<year>2010</year>) <volume>89</volume>(<issue>2</issue>):<fpage>556</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.10.050</pub-id><pub-id pub-id-type="pmid">20103341</pub-id>
</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkis</surname><given-names>V</given-names></name><name><surname>Sreeram</surname><given-names>N</given-names></name><name><surname>Trieschmann</surname><given-names>U</given-names></name><name><surname>Mime</surname><given-names>LB</given-names></name><name><surname>Bennink</surname><given-names>G</given-names></name></person-group>. <article-title>Comparison of arrhythmia incidence after the extracardiac conduit versus the intracardiac lateral tunnel fontan completion</article-title>. <source>Int J Cardiol</source>. (<year>2011</year>) <volume>146</volume>(<issue>2</issue>):<fpage>258</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2010.10.070</pub-id><pub-id pub-id-type="pmid">21093080</pub-id>
</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azakie</surname><given-names>A</given-names></name><name><surname>McCrindle</surname><given-names>BW</given-names></name><name><surname>Van Arsdell</surname><given-names>G</given-names></name><name><surname>Benson</surname><given-names>LN</given-names></name><name><surname>Coles</surname><given-names>J</given-names></name><name><surname>Hamilton</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Extracardiac conduit versus lateral tunnel cavopulmonary connections at a single institution: impact on outcomes</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2001</year>) <volume>122</volume>(<issue>6</issue>):<fpage>1219</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1067/mtc.2001.116947</pub-id><pub-id pub-id-type="pmid">11726899</pub-id>
</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>AC</given-names></name><name><surname>Turrentine</surname><given-names>M</given-names></name><name><surname>Rodefeld</surname><given-names>M</given-names></name><name><surname>Vijay</surname><given-names>P</given-names></name><name><surname>Schwartz</surname><given-names>TL</given-names></name><name><surname>Virgo</surname><given-names>KS</given-names></name><etal/></person-group>
<article-title>Fontan operation: a comparison of lateral tunnel with extracardiac conduit</article-title>. <source>Ann Thorac Surg</source>. (<year>2007</year>) <volume>83</volume>(<issue>2</issue>):<fpage>622</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2006.09.070</pub-id><pub-id pub-id-type="pmid">17257998</pub-id>
</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>DL</given-names></name><name><surname>Dibardino</surname><given-names>DJ</given-names></name><name><surname>Braud</surname><given-names>BE</given-names></name><name><surname>Fenrich</surname><given-names>AL</given-names></name><name><surname>Heinle</surname><given-names>JS</given-names></name><name><surname>Vaughn</surname><given-names>WK</given-names></name><etal/></person-group>
<article-title>Salvaging the failing fontan: lateral tunnel versus extracardiac conduit</article-title>. <source>Ann Thorac Surg</source>. (<year>2005</year>) <volume>80</volume>(<issue>4</issue>):<fpage>1445</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.athoracsur.2005.03.112</pub-id><pub-id pub-id-type="pmid">16181885</pub-id>
</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakacova</surname><given-names>N</given-names></name><name><surname>Lakomy</surname><given-names>M</given-names></name><name><surname>Kovacikova</surname><given-names>L</given-names></name></person-group>. <article-title>Arrhythmias after fontan operation: comparison of lateral tunnel and extracardiac conduit</article-title>. <source>J Electrocardiol</source>. (<year>2008</year>) <volume>41</volume>(<issue>2</issue>):<fpage>173</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jelectrocard.2007.10.007</pub-id><pub-id pub-id-type="pmid">18328341</pub-id>
</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>JC</given-names></name><name><surname>Goldberg</surname><given-names>C</given-names></name><name><surname>Bove</surname><given-names>EL</given-names></name><name><surname>Salehian</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Ohye</surname><given-names>RG</given-names></name><etal/></person-group>
<article-title>Fontan operation in the current era: a 15-year single institution experience</article-title>. <source>Ann Surg</source>. (<year>2008</year>) <volume>248</volume>(<issue>3</issue>):<fpage>402</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0b013e3181858286</pub-id><pub-id pub-id-type="pmid">18791360</pub-id>
</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>LK</given-names></name><name><surname>Rosenthal</surname><given-names>DN</given-names></name><name><surname>Reitz</surname><given-names>BA</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Dubin</surname><given-names>AM</given-names></name></person-group>. <article-title>Arrhythmias and thromboembolic complications after the extracardiac fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>1998</year>) <volume>115</volume>(<issue>3</issue>):<fpage>499</fpage>&#x02013;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-5223(98)70311-3</pub-id><pub-id pub-id-type="pmid">9535435</pub-id>
</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavey</surname><given-names>REW</given-names></name><name><surname>Gaum</surname><given-names>WE</given-names></name><name><surname>Byrum</surname><given-names>CJ</given-names></name><name><surname>Smith</surname><given-names>FC</given-names></name><name><surname>Kveselis</surname><given-names>DA</given-names></name></person-group>. <article-title>Loss of sinus rhythm after total cavopulmonary connection</article-title>. <source>Circulation</source>. (<year>1995</year>) <volume>92</volume>(<issue>9</issue>):<fpage>304</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.92.9.304</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AW</given-names></name><name><surname>Veldtman</surname><given-names>G</given-names></name></person-group>. <article-title>Heart rate responses during exercise by dominant ventricle in pediatric and young adult patients with a fontan circulation</article-title>. <source>Can J Cardiol</source>. (<year>2020</year>) <volume>36</volume>(<issue>9</issue>):<fpage>1508</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.cjca.2019.10.042</pub-id><pub-id pub-id-type="pmid">32249066</pub-id>
</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claessen</surname><given-names>G</given-names></name><name><surname>La Gerche</surname><given-names>A</given-names></name><name><surname>Van De Bruaene</surname><given-names>A</given-names></name><name><surname>Claeys</surname><given-names>M</given-names></name><name><surname>Willems</surname><given-names>R</given-names></name><name><surname>Dymarkowski</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Heart rate reserve in fontan patients: chronotropic incompetence or hemodynamic limitation?</article-title>
<source>J Am Heart Assoc</source>. (<year>2019</year>) <volume>8</volume>(<issue>9</issue>):<fpage>e012008</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.119.012008</pub-id><pub-id pub-id-type="pmid">31041880</pub-id>
</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedlund</surname><given-names>ER</given-names></name><name><surname>S&#x000f6;derstr&#x000f6;m</surname><given-names>L</given-names></name><name><surname>Lundell</surname><given-names>B</given-names></name></person-group>. <article-title>Appropriate heart rate during exercise in fontan patients</article-title>. <source>Cardiol Young</source>. (<year>2020</year>) <volume>30</volume>(<issue>5</issue>):<fpage>674</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1017/S1047951120000761</pub-id><pub-id pub-id-type="pmid">32299527</pub-id>
</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>AS</given-names></name><name><surname>Mikkelsen</surname><given-names>UR</given-names></name><name><surname>Idorn</surname><given-names>L</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>KE</given-names></name><name><surname>Thilen</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Hemodynamic causes of exercise intolerance in fontan patients</article-title>. <source>Int J Cardiol</source>. (<year>2014</year>) <volume>175</volume>(<issue>3</issue>):<fpage>478</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2014.06.015</pub-id><pub-id pub-id-type="pmid">25023794</pub-id>
</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crystal</surname><given-names>GJ</given-names></name><name><surname>Salem</surname><given-names>MR</given-names></name></person-group>. <article-title>The bainbridge and the &#x0201c;reverse&#x0201d; bainbridge reflexes: history, physiology, and clinical relevance</article-title>. <source>Anesth Analg</source>. (<year>2012</year>) <volume>114</volume>(<issue>3</issue>):<fpage>520</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1213/ANE.0b013e3182312e21</pub-id><pub-id pub-id-type="pmid">21965361</pub-id>
</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Azevedo</surname><given-names>IM</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Dreifus</surname><given-names>LS</given-names></name></person-group>. <article-title>Atrioventricular junctional rhythm: classification and clinical significance</article-title>. <source>Chest</source>. (<year>1973</year>) <volume>64</volume>:<fpage>732</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1378/chest.64.6.732</pub-id><pub-id pub-id-type="pmid">4128193</pub-id>
</mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Januszewska</surname><given-names>K</given-names></name><name><surname>Schuh</surname><given-names>A</given-names></name><name><surname>Lehner</surname><given-names>A</given-names></name><name><surname>Dalla-Pozza</surname><given-names>R</given-names></name><name><surname>Malec</surname><given-names>E</given-names></name></person-group>. <article-title>Lateral atrial tunnel fontan operation predisposes to the junctional rhythm</article-title>. <source>Pediatr Cardiol</source>. (<year>2017</year>) <volume>38</volume>:<fpage>712</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-017-1571-3</pub-id><pub-id pub-id-type="pmid">28184977</pub-id>
</mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>I</given-names></name><name><surname>Shehu</surname><given-names>N</given-names></name><name><surname>Stern</surname><given-names>H</given-names></name><name><surname>Meierhofer</surname><given-names>C</given-names></name></person-group>. <article-title>Junctional rhythm produces retrograde flow in the whole fontan system: cardiac magnetic resonance&#x02013;derived flow documentation&#x02014;a case report</article-title>. <source>Eur Heart J Case Rep</source>. (<year>2023</year>) <volume>7</volume>(<issue>3</issue>):<fpage>ytad126</fpage>. <pub-id pub-id-type="doi">10.1093/ehjcr/ytad126</pub-id><pub-id pub-id-type="pmid">37006796</pub-id>
</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasselman</surname><given-names>T</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Madan</surname><given-names>N</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name></person-group>. <article-title>Reversal of fenestration flow during ventricular systole in fontan patients in junctional or ventricular paced rhythm</article-title>. <source>Pediatr Cardiol</source>. (<year>2005</year>) <volume>26</volume>:<fpage>638</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-005-0879-6</pub-id><pub-id pub-id-type="pmid">16132285</pub-id>
</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balaji</surname><given-names>S</given-names></name><name><surname>Evers</surname><given-names>PD</given-names></name><name><surname>Batra</surname><given-names>AS</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name></person-group>. <article-title>Management of junctional rhythm in patients after the fontan operation: a multicenter congenital cardiology survey</article-title>. <source>Pediatr Cardiol</source>. (<year>2024</year>) <volume>45</volume>(<issue>1</issue>):<fpage>63</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-023-03296-6</pub-id><pub-id pub-id-type="pmid">37740738</pub-id>
</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>BJ</given-names></name><name><surname>Batra</surname><given-names>AS</given-names></name><name><surname>Burch</surname><given-names>GH</given-names></name><name><surname>Shen</surname><given-names>I</given-names></name><name><surname>Ungerleider</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>JW</given-names></name><etal/></person-group>
<article-title>Acute hemodynamic effects of pacing in patients with fontan physiology: a prospective study</article-title>. <source>J Am Coll Cardiol</source>. (<year>2005</year>) <volume>46</volume>(<issue>10</issue>):<fpage>1937</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2005.07.045</pub-id><pub-id pub-id-type="pmid">16286183</pub-id>
</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poh</surname><given-names>CL</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name><name><surname>Grigg</surname><given-names>LE</given-names></name><name><surname>Kalman</surname><given-names>JM</given-names></name><name><surname>McGuire</surname><given-names>MA</given-names></name><name><surname>Gentles</surname><given-names>TL</given-names></name><etal/></person-group>
<article-title>Pacemakers are associated with a higher risk of late death and transplantation in the fontan population</article-title>. <source>Int J Cardiol</source>. (<year>2019</year>) <volume>282</volume>:<fpage>33</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2019.01.088</pub-id><pub-id pub-id-type="pmid">30755335</pub-id>
</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RV</given-names></name><name><surname>Travison</surname><given-names>T</given-names></name><name><surname>Kaltman</surname><given-names>JR</given-names></name><name><surname>Cecchin</surname><given-names>F</given-names></name><name><surname>Colan</surname><given-names>SD</given-names></name><name><surname>Idriss</surname><given-names>SF</given-names></name><etal/></person-group>
<article-title>Comparison of fontan survivors with and without pacemakers: a report from the pediatric heart network fontan cross-sectional study</article-title>. <source>Congenit Heart Dis</source>. (<year>2013</year>) <volume>8</volume>(<issue>1</issue>):<fpage>32</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0803.2012.00692.x</pub-id><pub-id pub-id-type="pmid">22762157</pub-id>
</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>MI</given-names></name><name><surname>Rhodes</surname><given-names>LA</given-names></name><name><surname>Wernovsky</surname><given-names>G</given-names></name><name><surname>Gaynor</surname><given-names>JW</given-names></name><name><surname>Spray</surname><given-names>TL</given-names></name><name><surname>Rychik</surname><given-names>J</given-names></name></person-group>. <article-title>Atrial pacing: an alternative treatment for protein-losing enteropathy after the fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. (<year>2001</year>) <volume>121</volume>(<issue>3</issue>):<fpage>582</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1067/mtc.2001.110681</pub-id><pub-id pub-id-type="pmid">11241095</pub-id>
</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinemann</surname><given-names>MK</given-names></name><name><surname>Gass</surname><given-names>M</given-names></name><name><surname>Breuer</surname><given-names>J</given-names></name><name><surname>Ziemer</surname><given-names>G</given-names></name></person-group>. <article-title>DDD pacemaker implantation after fontan-type operations</article-title>. <source>Pacing Clin Electrophysiol</source>. (<year>2003</year>) <volume>26</volume>(<issue>1p2</issue>):<fpage>492</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1046/j.1460-9592.2003.00079.x</pub-id><pub-id pub-id-type="pmid">12687875</pub-id>
</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>BJ</given-names></name><name><surname>Burch</surname><given-names>GH</given-names></name><name><surname>Tripple</surname><given-names>D</given-names></name><name><surname>Balaji</surname><given-names>S</given-names></name></person-group>. <article-title>Resolution of plastic bronchitis with atrial pacing in a patient with fontan physiology</article-title>. <source>Pediatr Cardiol</source>. (<year>2004</year>) <volume>25</volume>:<fpage>73</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-003-0529-9</pub-id><pub-id pub-id-type="pmid">14534762</pub-id>
</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alnoor</surname><given-names>M</given-names></name><name><surname>Burch</surname><given-names>G</given-names></name><name><surname>Armsby</surname><given-names>L</given-names></name><name><surname>Batra</surname><given-names>A</given-names></name><name><surname>Balaji</surname><given-names>S</given-names></name></person-group>. <article-title>Hemodynamic impact of atrial pacing in patients with fontan physiology and junctional rhythm: a cardiac catheterization study</article-title>. <source>Pediatr Cardiol</source>. (<year>2022</year>) <volume>43</volume>:<fpage>508</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-021-02747-2</pub-id><pub-id pub-id-type="pmid">34661729</pub-id>
</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodama</surname><given-names>Y</given-names></name><name><surname>Kuraoka</surname><given-names>A</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ushinohama</surname><given-names>H</given-names></name><name><surname>Sagawa</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Outcome of patients with functional single ventricular heart after pacemaker implantation: what makes it poor, and what can we do?</article-title>
<source>Heart Rhythm</source>. (<year>2019</year>) <volume>16</volume>(<issue>12</issue>):<fpage>1870</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2019.06.019</pub-id><pub-id pub-id-type="pmid">31252085</pub-id>
</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chubb</surname><given-names>H</given-names></name><name><surname>Bulic</surname><given-names>A</given-names></name><name><surname>Mah</surname><given-names>D</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Janousek</surname><given-names>J</given-names></name><name><surname>Fumanelli</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Impact and modifiers of ventricular pacing in patients with single ventricle circulation</article-title>. <source>J Am Coll Cardiol</source>. (<year>2022</year>) <volume>80</volume>(<issue>9</issue>):<fpage>902</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2022.05.053</pub-id><pub-id pub-id-type="pmid">36007989</pub-id>
</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulic</surname><given-names>A</given-names></name><name><surname>Zimmerman</surname><given-names>FJ</given-names></name><name><surname>Ceresnak</surname><given-names>SR</given-names></name><name><surname>Shetty</surname><given-names>I</given-names></name><name><surname>Motonaga</surname><given-names>KS</given-names></name><name><surname>Freter</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Ventricular pacing in single ventricles&#x02014;a bad combination</article-title>. <source>Heart Rhythm</source>. (<year>2017</year>) <volume>14</volume>(<issue>6</issue>):<fpage>853</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2017.03.035</pub-id><pub-id pub-id-type="pmid">28528723</pub-id>
</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Shannon</surname><given-names>KM</given-names></name></person-group>. <article-title>Transpulmonary atrial pacing: an approach to transvenous pacemaker implantation after extracardiac conduit fontan surgery</article-title>. <source>J Cardiovasc Electrophysiol</source>. (<year>2014</year>) <volume>25</volume>(<issue>9</issue>):<fpage>1028</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/jce.12447</pub-id><pub-id pub-id-type="pmid">24786766</pub-id>
</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khairy</surname><given-names>P</given-names></name><name><surname>Landzberg</surname><given-names>MJ</given-names></name><name><surname>Gatzoulis</surname><given-names>MA</given-names></name><name><surname>Mercier</surname><given-names>LA</given-names></name><name><surname>Fernandes</surname><given-names>SM</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study</article-title>. <source>Circulation</source>. (<year>2006</year>) <volume>113</volume>(<issue>20</issue>):<fpage>2391</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.622076</pub-id><pub-id pub-id-type="pmid">16702467</pub-id>
</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Assaad</surname><given-names>I</given-names></name><name><surname>Pastor</surname><given-names>T</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>E</given-names></name><name><surname>Gauvreau</surname><given-names>K</given-names></name><name><surname>Rathod</surname><given-names>RH</given-names></name><name><surname>Gurvitz</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Atrial pacing in fontan patients: the effect of transvenous lead on clot burden</article-title>. <source>Heart Rhythm</source>. (<year>2021</year>) <volume>18</volume>(<issue>11</issue>):<fpage>1860</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2021.06.1191</pub-id><pub-id pub-id-type="pmid">34182172</pub-id>
</mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czosek</surname><given-names>RJ</given-names></name><name><surname>Anderson</surname><given-names>JB</given-names></name><name><surname>Baskar</surname><given-names>S</given-names></name><name><surname>Khoury</surname><given-names>PR</given-names></name><name><surname>Jayaram</surname><given-names>N</given-names></name><name><surname>Spar</surname><given-names>DS</given-names></name></person-group>. <article-title>Predictors and outcomes of heart block during surgical stage I palliation of patients with a single ventricle: a report from the NPC-QIC</article-title>. <source>Heart Rhythm</source>. (<year>2021</year>) <volume>18</volume>(<issue>11</issue>):<fpage>1876</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2021.05.019</pub-id><pub-id pub-id-type="pmid">34029735</pub-id>
</mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpawich</surname><given-names>PP</given-names></name><name><surname>Rabah</surname><given-names>R</given-names></name><name><surname>Haas</surname><given-names>JE</given-names></name></person-group>. <article-title>Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block</article-title>. <source>Pacing Clin Electrophysiol</source>. (<year>1999</year>) <volume>22</volume>(<issue>9</issue>):<fpage>1372</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1540-8159.1999.tb00631.x</pub-id><pub-id pub-id-type="pmid">10527019</pub-id>
</mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubin</surname><given-names>AM</given-names></name><name><surname>Janousek</surname><given-names>J</given-names></name><name><surname>Rhee</surname><given-names>E</given-names></name><name><surname>Strieper</surname><given-names>MJ</given-names></name><name><surname>Cecchin</surname><given-names>F</given-names></name><name><surname>Law</surname><given-names>IH</given-names></name><etal/></person-group>
<article-title>Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study</article-title>. <source>J Am Coll Cardiol</source>. (<year>2005</year>) <volume>46</volume>(<issue>12</issue>):<fpage>2277</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2005.05.096</pub-id><pub-id pub-id-type="pmid">16360058</pub-id>
</mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silka</surname><given-names>MJ</given-names></name><name><surname>Shah</surname><given-names>MJ</given-names></name><name><surname>Silva</surname><given-names>JNA</given-names></name><name><surname>Balaji</surname><given-names>S</given-names></name><name><surname>Beach</surname><given-names>CM</given-names></name><name><surname>Benjamin</surname><given-names>MN</given-names></name><etal/></person-group>
<article-title>2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary</article-title>. <source>Ann Pediatr Cardiol</source>. (<year>2022</year>) <volume>15</volume>(<issue>3</issue>):<fpage>323</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.4103/0974-2069.361245</pub-id><pub-id pub-id-type="pmid">36589659</pub-id>
</mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Maria</surname><given-names>MV</given-names></name><name><surname>Brown</surname><given-names>DW</given-names></name><name><surname>Cetta</surname><given-names>F</given-names></name><name><surname>Ginde</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>D</given-names></name><name><surname>Menon</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Surveillance testing and preventive care after fontan operation: a multi-institutional survey</article-title>. <source>Pediatr Cardiol</source>. (<year>2019</year>) <volume>40</volume>:<fpage>110</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-018-1966-9</pub-id><pub-id pub-id-type="pmid">30159585</pub-id>
</mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saley</surname><given-names>TP</given-names></name><name><surname>Patel</surname><given-names>ND</given-names></name><name><surname>Bar-Cohen</surname><given-names>Y</given-names></name><name><surname>Silka</surname><given-names>MJ</given-names></name><name><surname>Hill</surname><given-names>AC</given-names></name></person-group>. <article-title>Utility of surveillance ambulatory rhythm monitoring in the pediatric fontan population</article-title>. <source>Pediatr Cardiol</source>. (<year>2021</year>) <volume>42</volume>(<issue>6</issue>):<fpage>1442</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-021-02630-0</pub-id><pub-id pub-id-type="pmid">33963437</pub-id>
</mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czosek</surname><given-names>RJ</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Khoury</surname><given-names>PR</given-names></name><name><surname>Knilans</surname><given-names>TK</given-names></name><name><surname>Spar</surname><given-names>DS</given-names></name><name><surname>Marino</surname><given-names>BS</given-names></name></person-group>. <article-title>Utility of ambulatory monitoring in patients with congenital heart disease</article-title>. <source>Am J Cardiol</source>. (<year>2013</year>) <volume>111</volume>(<issue>5</issue>):<fpage>723</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2012.11.021</pub-id><pub-id pub-id-type="pmid">23246250</pub-id>
</mixed-citation></ref></ref-list></back></article>